The Most Common Types of Bacteria Species in Hospitals

Editors

Zainab Hussain Kareem
Department of Pathological Analysis, College of Science, University of Kufa

Eman Hassan Salem Saloum
Department of Pathological Analysis, College of Science, University of Kufa

Aqeel Adel Mohsen
Department of Pathological Analysis, College of Science, University of Kufa

Muhammad Khalil Salman
Department of Pathological Analysis, College of Science, University of Kufa

Diana Essam Kazem Obaid
Department of Pathological Analysis, College of Science, Dhi Qar University

AkiNik Publications®
New Delhi

Published By: *AkiNik Publications*

AkiNik Publications
169, C-11, Sector - 3,
Rohini, Delhi-110085, India
Toll Free (India) – 18001234070
Phone No.: 9711224068, 9911215212
Website: www.akinik.com
Email: akinikbooks@gmail.com

Editors: *Zainab Hussain Kareem, Eman Hassan Salem Saloum, Aqeel Adel Mohsen, Muhammad Khalil Salman and Diana Essam Kazem Obaid*

Publication Year: *2024*

Edition: *1st*

Pages: *53*

Paperback ISBN: *978-93-6135-217-1*

E-book ISBN: *978-93-6135-765-7*

Book DOI: *https://doi.org/10.22271/ed.book.2840*

Price: *₹325/-*

Registration Details

- *Printing Press License No.: F.1 (A-4) press 2016*
- *Trade Mark Registered Under*
  - *Class 16 (Regd. No.: 5070429)*
  - *Class 35 (Regd. No.: 5070426)*
  - *Class 41 (Regd. No.: 5070427)*
  - *Class 42 (Regd. No.: 5070428)*

Contents

Chapter - 1

Introduction to the Prevalence of Bacterial Species in Hospitals and Its Implications for Diagnosing and Treating Infections

Patients come to hospitals to receive medical care and heal from their ailments, but unfortunately, they may encounter additional challenges during their stay, namely hospital-acquired infections (HAIs) such as infections caused by bacteria. Even though hospital staff work tirelessly to minimize these HAIs, the hospital environment provides a favorable setting for bacteria to thrive. Among the most prevalent bacterial species found in hospitals that are likely to cause HAIs are Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus species, and Escherichia coli. Dealing with these bacteria can be incredibly difficult since they often exhibit antimicrobial resistance, and some have even developed resistance against the most powerful antibiotics available, like colistin and carbapenem. This comprehensive review delves into the various bacterial species commonly encountered in hospital settings, exploring their origins, unique characteristics, frequency of occurrence, and the resistance rates associated with their most commonly prescribed drugs. Starting with Staphylococcus aureus, it is worth noting that this bacterium is coagulase positive. In certain circumstances, it can be found on human skin, upper respiratory systems, and gastrointestinal tracts. One of its major challenges lies in its ability to develop antimicrobial resistance through mechanisms such as the synthesis of penicillinase, an enzyme that grants resistance against penicillin antibiotics. When the gene carrying this enzyme exhibits resistance to the antibiotic, the bacterium is known as MRSA, or methicillin-resistant Staphylococcus aureus. Clinically, it has also exhibited resistance to other antibiotics like erythromycin, clindamycin, and gentamicin. Interestingly, the presence of these antibiotics actually triggers the activation of fusidic acid resistance genes in S. aureus. However, in S. aureus infections, high-level resistance to fusidic acid may occur as a result. It is important to mention that Staphylococcus species have shown higher rates of high-level fusidic acid resistance compared to other pathogens related to skin infections. Notably, the administration of topical or systemic antibiotics, especially when done within a timeframe of fewer than 3 months, is considered a significant risk factor associated with the development of high-level resistance to these drugs. In conclusion, the integration of telemedicine and other computer-related technologies within the practices of pharmacists has proven successful in implementing effective antibiotic stewardship programs. This approach has played a crucial role in curtailing the spread of MRSA, as it is predominately associated with healthcare facilities and poses a substantial threat to both local and regional levels of public health. The impact of MRSA on morbidity and mortality rates is significant, making it necessary to address and combat its spread diligently. Implementation of strict infection control measures, proper hand hygiene, appropriate use of antibiotics, and continuous education of healthcare professionals are essential in reducing the incidence and impact of HAIs caused by multidrug-resistant bacteria. (Aqel *et al*., 2023) (Eticha *et al*., 2022) (Abdeen *et al*. 2021) (Salamandane *et al*. 2022) (Becker *et al*. 2020) (Jibu *et al*. 2020) (Petrillo *et al*. 2021) (Abusleme *et al*. 2022).

Chapter - 2

Understanding Bacteria

Bacteria, the tiny organisms that are members of the prokaryotic domain, or what is a single-celled microscopic lifeform, don't have a cell nucleus, a cytoplasmic membrane-bound structure. They are seen in many different forms and sizes as they can be spherical, rod-like, or spiral. They can exist as single cells, in pairs, as chains, or as groups. On some environmental grounds, certain types of bacteria can be resistant to antibacterial drugs. Every living thing is made up of one or more cells, including bacterium. They are omnipresent. Some bacteria are beneficial to humans, flora, and fauna. They support in the digestion process and play a significant role in the environment. Even if antibiotics are not used on bacteria for a long period of time, person-to-person viral mutational shifts can be shifted. They can multiply by picking up genes from other bacteria in closed quarters. Because they kill bacteria or block their growth, antibacterial medications seem to be the most widely used of all drugs. Although viruses cannot be destroyed by antibiotics, many individuals keep asking for them because of the common colds, caused by viruses. It is common for some bacterial species to inhabit and spread throughout some sections of health care facilities. In facilities such as hospitals, sickbay wards, rehabilitation and long-term care services, they can be found all over the world. When it spreads around hospitals, it can pose a possible risk to patients. The ability to understand the kind of bacteria that is present at each hospital, consider whether they are weakened, and decide on the hospitals where they can be present is equivalent to fundamentally promoting the advanced techniques as well as setting the funds relevant for disease control. In addition, the identification and monitoring of bacterial species in healthcare settings leads to a better understanding of their behaviors and characteristics, ultimately aiding in the development of effective preventive measures and treatment strategies. Furthermore, the constant surveillance and analysis of bacteria in hospitals and healthcare facilities play a crucial role in minimizing the spread of infections and controlling outbreaks. By implementing strict hygiene protocols, regular disinfection practices, and targeted interventions, healthcare professionals can mitigate the risks associated with bacterial colonization and transmission. Moreover, advancements in technology have revolutionized bacterial detection and identification methods, allowing for quicker and more accurate analyses of bacterial samples. This has greatly improved our ability to respond promptly to potential threats and tailor antimicrobial therapies accordingly. As we continue to expand our knowledge on bacterial diversity and adaptation, it is imperative that we prioritize research and investment in infection control measures to safeguard public health and enhance patient safety. Through interdisciplinary collaborations and global cooperation, we can overcome the challenges posed by bacterial infections and pave the way for a healthier, more resilient future. It is of utmost importance that we remain vigilant in our efforts to combat bacterial infections and ensure the well-being of individuals and communities worldwide. (O'Toole, 2021) (Voidazan *et al*. 2020) (Weiner-Lastinger *et al*. 2020) (Jernigan *et al*. 2020) (Nelson *et al*. 2022) (Mackuľak *et al*. 2021) (Weiner-Lastinger *et al*. 2020) (Nelson *et al*. 2021).

Chapter - 3

The Importance of Bacteria in Hospital Settings

Hospitals are crucial places in the modern world where people can get the medical help that they need. It is of utmost importance that they maintain an exceptionally clean and sterile environment. The unfortunate reality is that within hospital walls, a wide variety of organisms, namely bacteria, fungi, and viruses, can be found. These microorganisms are pervasive and present a significant challenge to the overall cleanliness of the facility. In order to effectively combat this issue, comprehensive knowledge about the most common types of bacteria found in hospitals is imperative. Among the various types of bacteria, staphylococci play a prominent role. They are typically present on people's skin and even inhabit their nasal cavities. Staphylococci, in particular, are often associated with hospital-acquired infections, which makes them a matter of grave concern. Indeed, they are one of the most prevalent bacteria responsible for such infections. Recognizing the gravity of this issue, hospitals frequently isolate individuals found to carry staphylococci, in an effort to limit the potential spread of these bacteria to other patients. By taking these precautionary measures, hospitals strive to minimize the risk of infection and safeguard the well-being of their patients. Another significant group of bacteria worth mentioning are the pseudomonads, which, along with staphylococci, constitute a substantial portion of hospital-acquired infections. Pseudomonads, known for their resilience, can thrive in diverse environments, extending beyond hospital settings. Besides being found in swimming pools, they can also be identified as the culprits behind urinary tract infections. Aptly named, Escherichia coli is a bacterium primarily found in the human intestinal tract. Its presence in other areas of the body, such as the urinary system, indicates the occurrence of an infection. Moreover, when Escherichia coli is detected in the urinary tract, it serves as an indicator of the patient's length of stay in the hospital. Therefore, monitoring the frequency of bacteria in the urinary tract and wounds is fundamental to evaluating the overall cleanliness and maintenance efforts of the hospital. In conclusion, the presence of bacteria in hospitals poses a significant challenge. Staphylococci, pseudomonads, and Escherichia coli are among the most commonly encountered types of bacteria within these medical facilities. The isolation and careful management of patients carrying such bacteria are vital in upholding the strict standards of cleanliness and minimizing the risk of infections. By staying vigilant and continuously evaluating the frequency of bacteria in specific areas of the hospital, medical institutions can ensure they are maintaining a safe and hygienic environment for their patients. Therefore, it is essential for hospitals to implement effective measures and protocols to prevent the spread and minimize the impact of these harmful microorganisms. By doing so, they can contribute to the overall well-being and recovery of their patients, which remains their ultimate goal. The responsibility of hospital staff and administrators, in this regard, is paramount. They must prioritize the implementation and enforcement of stringent cleanliness practices, including regular disinfection of all surfaces, thorough hand hygiene, and appropriate waste management. Adequate training and education should be provided to all healthcare workers to ensure they are well-equipped with the knowledge and skills to effectively prevent and control the spread of infections. In addition, hospitals should invest in advanced technologies and equipment to facilitate the detection and eradication of bacteria within their premises. Regular surveillance and monitoring of bacterial counts and types can provide valuable insights into the effectiveness of cleaning procedures and help identify areas that require special attention. Collaboration and communication between different departments and healthcare professionals are also crucial in maintaining a coordinated and comprehensive approach towards infection control. Ultimately, the collective efforts of everyone involved in the healthcare system, from hospital management to healthcare workers to patients themselves, are necessary to successfully combat the challenges posed by bacteria in hospitals and ensure a safe environment for the delivery of quality healthcare services. (Tsouklidis *et al*., 2020) (Grasselli *et al*. 2021) (Sevin *et al*. 2021) (Pickens and Wunderink2022) (Samia *et al*., 2022) (Boussion *et al*. 2021).

Chapter - 4

Methodologies for Identifying Bacteria Species

Since the inception of molecular biology methodologies in 2008, hospitals have extensively utilized these techniques to identify and differentiate various species of bacteria within a healthcare environment. It is crucial to note that the interest in microbiological risk in hospitals started gaining traction during the latter half of the previous century, primarily because bacteria were exceedingly difficult to locate and identify back then. In the past, pharmaceutical companies had to visit hospitals to specifically search for bacteria associated with a patient's illness. Subsequently, tailored antibiotic treatments were administered to these patients based on the bacteria found. However, the scenario has dramatically evolved in the present era, with over 6,000 known bacterial species present. Consequently, it has become imperative to distinguish and classify these species accurately. This process is vital to prevent or minimize the risk of contamination, especially for high-risk patients in critical conditions, such as emergency room or intensive care patients who have significantly compromised natural bodily defenses. Importantly, immediate and effective utilization of molecular biology is equally crucial for reducing risks in patients with relatively suppressed immune systems, such as outpatients or individuals undergoing prolonged treatment periods, for instance, cancer patients receiving chemotherapy or organ transplant recipients undergoing immunosuppression protocols. These scenarios occur both within and outside the confines of the hospital setting. The ability to rapidly and accurately identify bacterial species would facilitate the evaluation of the anticipated impact of new hygiene guidelines, specialized wards, or hospital rooms equipped with novel materials like copper surfaces, or other contact surfaces treated with powerful disinfectants. Moreover, such advancements could enable researchers to systematically characterize the species present in a hospital's biological environment. This comprehensive analysis would provide valuable insights into the contribution of specific areas within the hospital to instances of hospital-acquired infections, encompassing both lung infections and infections originating externally. The latter significantly influences the rehospitalization rates of elderly individuals, who often suffer from various chronic diseases that render them more susceptible and fragile. (Janda & Abbott, 2021) (Maina, 2020) (Lloyd, 2023) (Barlandas-Quintana and Martinez-Ledesma 2020) (Bispo *et al*., 2022).

Chapter - 5

Common Bacteria Species in Hospitals

When left uncontrolled, harmful bacteria that cause diseases pose significant risks to the overall health of the population. Even if they are not directly disease-causing, certain types of bacteria are still considered to be of serious concern to public health. Due to their often-unfamiliar Latin names, many people mistakenly assume that the chances of being exposed to these bacteria are low. However, there is limited information available about the actual prevalence of these bacteria in the built environment. Creating practical tools specifically for use in hospital settings could greatly assist in documenting and managing human exposure to bacteria. Many bacteria found in hospitals can colonize healthy individuals without causing disease. However, aside from causing illness in healthy individuals, these bacteria can disproportionately affect people with weakened immune systems. Escherichia coli (*E. coli*) is derived from the fecal matter of animals and humans. Out of the numerous groups of *E. coli*, there are six that are harmful to humans. These groups consist only of a few strains found in the gastrointestinal tracts of animals and humans. Staphylococcus aureus is capable of causing serious illnesses and even death, in addition to minor skin infections. Similarly, *Enterococcus faecalis* (*E. faecalis*) rarely causes illness in certain patient subgroups, but it can still lead to disease in otherwise healthy individuals. Unlike most gastrointestinal bacteria, Listeria monocytogenes is able to evade the immune system by accessing cells that are meant to eradicate such bacteria through the gastrointestinal route. *Erysipelothrix rhusiopathiae*, a bacterium found in the gastrointestinal tracts of animals and humans, can also be found on the skin. If the skin becomes broken, it has the potential to cause illness by infecting the wound. It is crucial to fully comprehend the dangers posed by these pathogenic bacteria and the various ways in which they can severely impact public health. With their ability to cause diseases that range from mild to life-threatening, these bacteria must not be taken lightly. Although their Latin names may sound intimidating or unfamiliar, their potential to harm us is a very real and serious concern. The limited knowledge surrounding their presence in our surroundings only adds complexity to the management of the risks they impose. To effectively combat the detrimental effects of these bacteria, it is imperative that practical tools are developed specifically for hospital settings. These tools would play a vital role in accurately documenting the extent of human exposure to bacteria, as well as effectively managing and reducing such exposure. By providing a comprehensive understanding of the prevalence and distribution of these pathogenic bacteria in hospital environments, these tools can help implement targeted measures to safeguard the health of both patients and healthcare workers. It is important to note that not all bacteria found in hospitals are disease-causing. Many of them can coexist with humans without causing any illnesses. However, this does not mean that they are harmless. The same bacteria that may not harm a healthy individual can pose severe health risks to those with compromised immune systems. Therefore, it is crucial to consider the potential consequences for vulnerable populations. Among the harmful bacteria commonly found in hospitals, Escherichia coli (*E. coli*) stands out as a significant threat. Derived from the fecal matter of animals and humans, *E. coli* comprises six groups that have been identified as harmful to humans. Although only a few strains of *E. coli* reside in the gastrointestinal tracts of animals and humans, they have the potential to cause severe diseases and infections. Another bacterium worth mentioning is Staphylococcus aureus, which can cause a wide range of illnesses, from minor skin infections to life-threatening conditions. The ability of Staphylococcus aureus to induce serious illness and even death emphasizes the importance of implementing effective control and prevention measures. *Enterococcus faecalis* (*E. faecalis*) is another strain that deserves attention. While it is rarely pathogenic in certain patient subgroups, it can still cause disease in otherwise healthy individuals. This highlights the necessity for vigilance, as even seemingly harmless bacteria can pose a risk to public health under specific circumstances. Listeria monocytogenes, unlike most gastrointestinal bacteria, possesses the unique ability to evade the immune system. By gaining access to cells that are meant to eliminate such bacteria through the gastrointestinal route, Listeria monocytogenes can continue to thrive and cause infections. This evasive behavior makes Listeria monocytogenes a formidable foe that requires careful monitoring and containment measures. *Erysipelothrix rhusiopathiae*, a bacterium found in both the gastrointestinal tracts of animals and humans, also deserves attention. While it typically resides within the intestines, it can also colonize the skin. If the skin barrier becomes compromised, *Erysipelothrix rhusiopathiae* has the potential to cause illness and infect the broken skin. In conclusion, understanding the prevalence and dangers posed by these pathogenic bacteria is crucial for public health. By developing effective tools for documenting and managing human exposure to bacteria, we can strive towards minimizing the risks they impose. Additionally, emphasizing the importance of rigorous hygiene practices and preventive measures can aid in reducing the transmission and impact of these harmful bacteria in hospital settings and beyond. (Peng *et al*., 2024) (Puvača & de Llanos Frutos, 2021) (Riley, 2020) (EFSA *et al*. 2020) (Aworh *et al*. 2021) (Odonkor & Mahami, 2020) (Panel *et al*. 2020) (Zhang *et al*. 2020).

5.1 Staphylococcus aureus

Staphylococcus aureus is a gram-positive bacterium that commonly causes infections in hospitals, earning its reputation as a highly prevalent pathogen. Its ability to infect a large number of hospital patients is a cause for concern due to the extensive range of diseases it can cause. Staphylococcus aureus is known to induce various devastating conditions including skin infections, soft tissue infections, deep tissue infections, bacteremia, toxinoses, and endocarditis. What sets Staphylococcus aureus apart is its remarkable capability to evade human immune responses, making it a major contributor to healthcare-associated infections. Additionally, Staphylococcus aureus has the ability to resist common antimicrobial drugs used in healthcare settings, which is leading to an alarming increase in drug-resistant strains. It is estimated that at least 80% of methicillin-resistant Staphylococcus aureus (MRSA) isolates have the potential to infect humans. MRSA is of particular concern due to its heightened pathogenicity compared to methicillin-susceptible Staphylococcus aureus (MSSA). The wide colonization and infection of healthcare facilities by MRSA have put global healthcare systems to the test. The emergence of vancomycin-resistant, tetracycline-resistant, and other antimicrobial-resistant MRSA isolates is also troubling. Strains of Staphylococcus aureus with vancomycin resistance not only display high-level resistance to both vancomycin and teicoplanin, but they also showcase hypervirulence. This hypervirulence and drug resistance combination pose significant challenges in the treatment of infections caused by such strains. In conclusion, Staphylococcus aureus, especially MRSA, poses significant risks and demands special attention to prevent further transmission within communities and healthcare settings. Moreover, the economic burden associated with these infections is substantial, leading to increased pressure on healthcare systems globally. Efforts should focus on implementing rigorous infection control measures, developing new antimicrobial drugs, and promoting awareness among healthcare professionals and the public to effectively combat the threat of Staphylococcus aureus infections. (Cheung *et al*., 2021) (Rungelrath & DeLeo, 2021) (Park & Ronholm, 2021) (Algammal *et al*. 2020) (Pidwill *et al*. 2021) (Hardy *et al*. 2020) (Clegg *et al*. 2021).

5.2 Escherichia coli

Escherichia coli (commonly known as *E. coli*) is a rod-shaped, Gram-negative, flagellated, facultative anaerobe of the genus Escherichia that is commonly found in the lower intestine of warm-blooded organisms (endotherms). Most *E. coli* strains are harmless, but some serotypes (pathogenic strains) can cause serious food poisoning in their hosts and are occasionally responsible for product recalls due to food contamination. The harmless strains are part of the normal microbiota of the gut and can benefit their hosts by producing vitamin K2, preventing colonization of the intestine with pathogenic bacteria, having a symbiotic relationship, and training the immune system to respond only to pathogens. *E. coli* is expelled into the environment within fecal matter. The bacterium can survive for a short period outside the body, and when this happens, it can cause serious illness. *E. coli* is a type of bacteria that can be found in the gut, also known as the intestines. When *E. coli* find their way to other parts of the body or are transferred from one host to another, they can cause disease. In total, there are seven groups of *E. coli* that can cause disease in humans. Escherichia coli bacteria can also infect animals, like pigs and cows. The bacteria don't make the animals sick, but they can cause disease in humans who consume unpasteurized milk or undercooked meat from infected animals. Food can also become contaminated with *E. coli* if it comes into contact with feces when being prepared. Some people carry *E. coli* in their systems and don't get sick, but they can still spread the bacteria to others. Hundreds of people are sickened and forced to visit their doctors every year because of *E. coli* infections. A small percentage of these infections contribute to Hemolytic Uremic Syndrome, a dangerous kidney disease. Because of the diseases it can cause, *E. coli* is a serious concern in healthcare settings. Escherichia coli, also known as *E. coli*, is a rod-shaped, Gram-negative, flagellated, facultative anaerobe of the genus Escherichia that is commonly found in the lower intestine of warm-blooded organisms (endotherms). Most *E. coli* strains are harmless to their hosts, but it's important to be aware that certain serotypes, which are characterized as pathogenic strains, have the ability to cause severe food poisoning. In fact, these pathogenic strains can sometimes lead to product recalls due to contamination issues in food products. On the other hand, the harmless strains of *E. coli* play a beneficial role as part of the normal gut microbiota. They contribute to their hosts' well-being by producing vitamin K2, preventing the colonization of the intestine by pathogenic bacteria, establishing a symbiotic relationship, and training the immune system to selectively respond to pathogens. It's worth mentioning that when it comes to *E. coli*, it is primarily expelled into the environment through fecal matter. Although it can survive for a short period of time outside of the body, the presence of *E. coli* in the environment can result in serious illnesses. *E. coli* is a specific type of bacteria that is commonly found within the gut, also known as the intestines. However, if *E. coli* manages to spread to other parts of the body or is transferred from one host to another, it has the potential to cause diseases. Interestingly, researchers have identified a total of seven groups of *E. coli* that are known to cause diseases specifically in humans. In addition to its ability to infect humans, Escherichia coli bacteria can also infect animals like pigs and cows. While these bacteria don't cause any harm to the animals themselves, individuals who consume unpasteurized milk or undercooked meat from infected animals may be at risk of developing diseases. Furthermore, food can become contaminated with *E. coli* if it comes into contact with feces during preparation. It is worth mentioning that there are individuals who carry *E. coli* in their systems without any symptoms, yet they still have the potential to spread the bacteria to others. Unfortunately, *E. coli* infections result in hundreds of people falling ill every year, leading them to seek medical attention. Moreover, a small percentage of these infections can contribute to the development of Hemolytic Uremic Syndrome, a dangerous kidney disease. Due to the potential diseases it can cause, *E. coli* remains a significant concern when it comes to healthcare settings. (Benedict, 2023) (Todd, 2022) (Long *et al*. 2023) (Warmate & Onarinde, 2023) (Luu-Thi & Michiels, 2021) (Ehuwa *et al*., 2021) (Adefrash *et al*. 2024) (Masood *et al*. 2024).

5.3 Pseudomonas aeruginosa

Pseudomonas aeruginosa is a clinically significant bacterium and represents a growing concern in the realm of nosocomial infections. Worldwide, this bacterium is one of the principal causes of death in healthcare-associated infections. Colonies of Pseudomonas aeruginosa have been found to thrive in a refrigerated healthcare unit, agriculture and horticulture laboratory, women's ward, haematology department, surgical ward, and multispecialty intensive care unit. These diverse environments provide ample opportunities for Pseudomonas aeruginosa to spread and cause harm. In terms of patient composition, some reports highlight a high concentration of immunosuppressed patients including those undergoing chemotherapy or with underlying health conditions. To fully understand the risk genesis associated with Pseudomonas aeruginosa infections and to improve process management, it is crucial to delve into its characteristics. Pseudomonas aeruginosa is a rod-shaped, aerobic, and Gram-negative bacillus. It has the ability to form infections in both humans and plants. What makes Pseudomonas aeruginosa particularly worrisome is its adaptability and resilience, allowing it to thrive in almost any environment, including surfaces and hospital equipment. This versatility poses a significant challenge to infection control in healthcare settings. Moreover, Pseudomonas aeruginosa is associated with numerous health concerns as it is linked to many common illnesses and conditions that are most likely to be diagnosed. Its adherence properties with host skin and other inanimate surfaces make it almost impossible to contain its spread. In healthcare settings, this presents a major problem, as Pseudomonas aeruginosa is a nosocomial pathogen, meaning it is commonly acquired in healthcare facilities. It acts as an opportunistic pathogen, primarily targeting the mucous membranes of individuals with weakened immune defenses. It often attacks vital organs, resulting in severe and potentially life-threatening infections. Further complicating matters, Pseudomonas aeruginosa has a high resistance rate to antibiotics. This necessitates the use of specific antibiotics that possess particular pharmacokinetic properties to effectively combat the bacterium. Additionally, Pseudomonas aeruginosa has the ability to form a biofilm, further enhancing its ability to cause infection and evade treatment measures. Overall, Pseudomonas aeruginosa is responsible for a wide range of infections, with a predilection for the respiratory tract, urinary tract, various tissues, burns, eyes, outer ear (causing otitis externa), and even the external canal. It is capable of triggering life-threatening diseases such as meningitis, endocarditis, and pneumonia. Given its ability to adapt, resist treatment, and thrive in various settings, finding strategies to combat Pseudomonas aeruginosa and prevent its spread is of utmost importance in ensuring patient safety and reducing healthcare-associated infections. In conclusion, understanding the complex nature of Pseudomonas aeruginosa and its impact on healthcare settings is critical in developing effective prevention and control measures. Expanding the text: Pseudomonas aeruginosa is a clinically significant and highly virulent bacterium that has become a formidable and widespread concern in the realm of nosocomial infections. This multidrug-resistant pathogen, known for its adaptability and resilience, has garnered international attention due to its role as a leading cause of mortality in healthcare-associated infections. The prevalence of Pseudomonas aeruginosa colonies has been observed not only in various clinical hospital units such as the refrigerated healthcare unit, agriculture and horticulture laboratory, women's ward, haematology department, surgical ward, and multispecialty intensive care unit, but also in unexpected settings, increasing the risk of transmission and subsequent harm. Its ability to thrive in diverse environments contributes to its alarming spread and the severity of the infections it generates. To effectively manage and mitigate the impact of Pseudomonas aeruginosa infections, an in-depth understanding of its complex characteristics is imperative. Pseudomonas aeruginosa, a rod-shaped, aerobic, and Gram-negative bacillus, is not limited to causing infections in humans; it also poses a significant threat to plants. The bacterium's adaptability to diverse environments, including various surfaces and hospital equipment, further heightens the challenge of infection control in healthcare settings. Additionally, the association between Pseudomonas aeruginosa and multiple common illnesses underscores its broad impact and diagnostic significance. Its remarkable ability to adhere to host skin and inanimate surfaces presents a formidable challenge in controlling its rampant dissemination. Within healthcare settings, the prevalence of Pseudomonas aeruginosa as a nosocomial pathogen, with a propensity for infecting individuals with compromised immune defenses, exacerbates the gravity of the situation. By primarily targeting the mucous membranes, Pseudomonas aeruginosa infiltrates vital organs, leading to severe and potentially life-threatening infections. Compounding the problem, this bacterium exhibits a high resistance rate to antibiotics, necessitating the use of specific medications with unique pharmacokinetic properties to effectively combat its virulence. Moreover, the formation of biofilms by Pseudomonas aeruginosa fortifies its ability to cause persistent infections and evade conventional treatment measures, presenting substantial obstacles to successful therapeutic interventions. Infecting various anatomical sites, Pseudomonas aeruginosa poses a serious threat to multiple organs and systems. Its predilection for infecting the respiratory tract, urinary tract, various tissues, burns, eyes, outer ear (causing otitis externa), and even the external canal manifests in debilitating diseases such as meningitis, endocarditis, and pneumonia that can have devastating consequences. The versatility of Pseudomonas aeruginosa, coupled with its ability to adapt, survive under unfavorable conditions, and resist treatment, emphasizes the urgent need to develop effective strategies to combat its spread and prevent its dire impact on patient safety and healthcare-associated infections. Only by comprehending the intricate nature of Pseudomonas aeruginosa and its far-reaching influence on healthcare settings can the development of robust prevention and control measures be achieved. In conclusion, recognizing the multifaceted nature of Pseudomonas aeruginosa and its pervasive presence in healthcare settings is paramount to the formulation of comprehensive and successful prevention and control strategies. By addressing the challenges posed by this highly resilient pathogen, healthcare systems can better safeguard patient well-being and mitigate the risks associated with healthcare-associated infections. (Erdem *et al*. 2022) (Voidazan *et al*. 2020) (Farzin *et al*., 2023) (Kontula *et al*. 2022) (Salmanov *et al*. 2023) (Spagnolo *et al*. 2021) (Haque *et al*. 2020).

5.4 *Enterococcus faecalis*

Because it does not require a host to survive and is capable of adhering to and forming biofilms on nonliving surfaces, this bacterium possesses the inherent ability to persist and flourish in the nosocomial environment. Due to its adaptability, it represents the most prevalent bacterium in a nosocomial setting, accounting for an estimated 34% to 67% of Enterococcus spp. isolated from the Intensive Care Unit. Enterococci are facultative anaerobes and a substantial number of strains exhibit remarkable resilience to a wide range of environmental stresses, including desiccation. Once introduced to a non-host environment, they display a propensity for replication, enhanced tolerance to environmental stressors, and the establishment of a prolonged reservoir in nosocomial settings. *E. faecalis*, specifically, stands out as the primary bacterial species responsible for nosocomial or hospital-acquired infective endocarditis. Notably, *E. faecalis* infections often display intrinsic and acquired multidrug resistance. In fact, this bacterium has the remarkable capability of transferring genetic material that codes for antibiotic resistance, thereby playing a pivotal role in the emergence of multidrug-resistant bacteria within the hospital environment. Similar to the other pathogens discussed, *E. faecalis* can also cause opportunistic infections, targeting individuals with weakened immune systems, such as those enduring prolonged hospital stays and frequent interventions and/or procedures related to their underlying condition. Furthermore, *E. faecalis* possesses a diverse array of virulence factors that contribute to its pathogenicity, including the production of cytolysin, which induces cell lysis and tissue damage. Moreover, it has the capacity to form aggregates and generate biofilms, enabling its survival in the formidable conditions presented by medical equipment and surfaces. The adaptability of *E. faecalis* is further underscored by its ability to acquire antibiotic resistance genes through horizontal gene transfer, ultimately resulting in the emergence of multidrug-resistant strains. Consequently, the expulsion of *E. faecalis* from healthcare environments poses a significant challenge, necessitating stringent implementation of infection control measures while encouraging the development of innovative treatment strategies to combat this formidable pathogen. Given its astonishing capability to endure and thrive in the nosocomial environment, it is imperative for healthcare facilities to prioritize the prevention and containment of *E. faecalis* infections. Through the implementation of meticulous cleaning and disinfection protocols, the promotion of proper hand hygiene, and the endorsement of antimicrobial stewardship, healthcare providers can effectively work towards minimizing the transmission and impact of this resilient bacterium. Furthermore, continuous research and surveillance are fundamental in comprehending the mechanisms of *E. faecalis* resistance and identifying novel approaches to treatment and prevention. By adopting a comprehensive approach that encompasses various strategies, we can diligently strive to alleviate the burden of *E. faecalis* infections and enhance patient safety within healthcare settings. It is of utmost importance for healthcare professionals to be vigilant and proactive in combating this persistent bacterium, as its prevalence and ability to cause severe infections continue to pose significant challenges in the field of healthcare. In conclusion, *E. faecalis*, with its tenacity and adaptability, remains a formidable pathogen within the nosocomial environment. Its ability to survive on nonliving surfaces, form biofilms, and transfer antibiotic resistance genes highlights the need for proactive measures to prevent and contain its spread. Through rigorous infection control protocols, robust surveillance, and innovative treatment strategies, healthcare facilities can strive to minimize the impact of *E. faecalis* infections and enhance patient safety. It is an ongoing battle that requires continuous research and collaboration among healthcare professionals to stay one step ahead of this resilient bacterium. By prioritizing prevention and implementing comprehensive strategies, we can work towards a future where *E. faecalis* infections are greatly reduced, and patient outcomes are improved. (Ayobami *et al*. 2020) (Davis *et al*. 2020) (López-Luis *et al*. 2021) (Lupia *et al*. 2022) (Herrera-Hidalgo *et al*. 2023) (Uda *et al*. 2021) (Iancu *et al*. 2023).

5.5 Acinetobacter baumannii

The Acinetobacter baumannii is a relatively common bacteria with a distinctive yellow pigmentation that is commonly found in various territories within the hospital setting, such as the cardiac ICU, as well as on both ventilatory equipment and in the human respiratory system. It should be noted that this species within hospitals is nearly all inherently resistant to ceftazidime, a broad-spectrum antibiotic widely used for treating infections, and is frequently also found to be resistant to ciprofloxacin, a fluoroquinolone antibiotic, and imipenem, a carbapenem antibiotic. Due to its resistance to various antibiotics, treating infections caused by Acinetobacter baumannii can be quite challenging. The Acinetobacter baumannii is not likely to be a major cause of illness in healthy individuals, as their immune systems can usually combat the bacteria effectively. However, for those under hospital care that are suffering from diseases like lung abscesses, burns, ventilator-acquired pneumonia, or wound infections, this bacterium becomes a significant potential pathogen. In these cases, Acinetobacter baumannii infections can lead to severe complications and prolonged hospital stays. Interestingly, Acinetobacter baumannii has the ability to remain dormant for extended periods of time, up to one and a half years, before manifesting in the form of a host infection. This unique characteristic poses a challenge in identifying and controlling the spread of the bacteria within healthcare settings. Given the potential risks associated with Acinetobacter baumannii infections, it is crucial to closely monitor and implement strict infection control measures in healthcare settings. Understanding the timing and methods of implementing these measures can help mitigate the spread of the bacteria and protect vulnerable individuals under hospital care. Unfortunately, the mortality rate following a nosocomial infection with Acinetobacter baumannii can vary significantly. It ranges from three percent to 29 percent, depending on factors such as the characteristics of the infected host and the location of the infection. This emphasizes the importance of early detection, effective management, and containment of Acinetobacter baumannii infections to minimize the impact on patient outcomes. In conclusion, Acinetobacter baumannii is a bacteria with significant implications in healthcare settings. Its antibiotic resistance and ability to cause severe infections in vulnerable individuals make it a critical pathogen to be aware of and actively manage. By implementing appropriate infection control measures and conducting further research, healthcare professionals can strive to minimize the impact of Acinetobacter baumannii infections and improve patient outcomes. The ongoing battle against Acinetobacter baumannii is multidimensional, requiring a comprehensive approach that encompasses not only clinical management but also public health guidelines, surveillance systems, and novel research endeavors. The development of new antibiotics or alternative therapeutic strategies could prove instrumental in combating this persistent and elusive bacterium. Moreover, promoting interdisciplinary collaborations among healthcare providers, researchers, and policy-makers will facilitate the exchange of knowledge and foster innovative approaches to address the challenges posed by Acinetobacter baumannii. It is imperative that the medical community remains vigilant in monitoring the evolution of this bacterium, as well as the emergence of novel resistance mechanisms. Additionally, continued education programs and awareness campaigns targeted at both healthcare professionals and the general public are vital in preventing the spread of Acinetobacter baumannii and minimizing its impact on public health. By uniting efforts and resources, we can strive for a future where the burden of Acinetobacter baumannii infections is significantly reduced, ultimately leading to improved patient care and outcomes. (Vázquez-López *et al*. 2020) (Kyriakidis *et al*., 2021) (Goldberg *et al*. 2021) (Li *et al*. 2022) (Yang *et al*. 2020) (Shi *et al*., 2024) (Nguyen & Joshi, 2021).

5.6 Clostridium difficile

Clostridium difficile infection (CDI) is a common addition to the list of bacterial species that are commonly found in healthcare settings. It holds the rank of being one of the "hospital superbugs" and manifests itself as antibiotic resistance and sporulation. It has the potential for the production of a multitude of toxins, a predilection for older populations, and challenges for healthcare such as the ability to form detectable endospores and resistance to household and hospital-grade disinfectants. The most current data indicates that some strains account for upwards of 33-39% of cases. Decreases in colonization and infection can be due to a lack of patient safety, effective handling of endospores, and maintaining a clean environment. Typical symptoms of C. difficile disease can include a mild or moderate case of diarrhea to more severe issues such as inflammation of the colon and the development of perforations, which can lead to sepsis and subsequent death. Despite efforts to curb the disease and transmission rates, C. difficile infection has continued to rise in all aspects of healthcare. Inpatient incidence alone from 2011-2012 of CDI was 0. 4 cases for every 1,000 patients, and while this does not signify a significant number of the population that has been afflicted, this is still a significant enough increase to warrant concerns, especially when looked at in the greater context of healthcare utilization. An area of particular concern for any hospital setting or other healthcare-associated venues can also include nosocomial changes to drug sensitivities of overall microflora on DNA and subsequently on the microbiome, which can have long-lasting after-effects on a patient’s overall health. Therefore, it is crucial to prioritize the prevention, containment, and management of Clostridium difficile infection. Implementing robust infection control measures, including proper hand hygiene, effective disinfection practices, and strict adherence to infection control protocols, can significantly reduce the transmission and incidence of CDI. Additionally, promoting antibiotic stewardship programs and education initiatives can help prevent unnecessary antibiotic use and reduce the risk of CDI development. Furthermore, continuous research and development of novel treatment options, such as new antibiotics and alternative therapies like fecal microbiota transplantation, can contribute to the effective management and eradication of CDI. Collaborative efforts between healthcare professionals, researchers, and policymakers are essential to combatting this challenging infection and ensuring patient safety in healthcare settings. By addressing the multifaceted aspects of Clostridium difficile infection, we can strive towards a future where CDI no longer poses a significant threat to public health. Through comprehensive strategies, vigilant surveillance, and a commitment to patient safety, we can work towards eliminating CDI and protecting the well-being of individuals in healthcare environments. In doing so, we can pave the way for a healthier and safer healthcare system for all. Clostridium difficile infection is a global healthcare issue of paramount importance. Infections caused by this bacteria have become increasingly prevalent in hospitals, nursing homes, and other healthcare facilities. CDI is considered a "hospital superbug" due to its ability to persist and spread within the healthcare environment. The rise of antibiotic resistance and the formation of endospores are key factors contributing to the challenge of managing this infection. Moreover, Clostridium difficile produces a wide array of toxins, exacerbating the severity of the disease. Elderly individuals are particularly vulnerable to CDI, and the infection can result in various complications ranging from mild to severe, including colon inflammation, perforations, sepsis, and, in worst-case scenarios, death. Despite concerted efforts to control the spread of C. difficile, its incidence continues to rise across all healthcare settings. Inpatient cases alone from 2011-2012 amounted to 0. 4 cases per 1,000 patients, underscoring the significance of this infection within the broader healthcare landscape. An additional concern is the impact of CDI on the bacterial microflora and subsequent effects on the patient's overall health. Nosocomial changes in drug sensitivities further complicate matters, highlighting the urgent need to prioritize the prevention, containment, and management of Clostridium difficile infection. Robust infection control measures must be implemented, including stringent hand hygiene practices, effective disinfection techniques, and unwavering adherence to infection control protocols. By doing so, the transmission and incidence of CDI can be significantly reduced. Promoting the judicious use of antibiotics through stewardship programs and educational initiatives is crucial in preventing unnecessary antibiotic usage and minimizing the risk of CDI development. Furthermore, continuous research and development of innovative treatment options, including novel antibiotics and alternative therapies such as fecal microbiota transplantation, hold promise in the effective management and eradication of CDI. In combating this challenging infection, collaboration among healthcare professionals, researchers, and policymakers is essential. By addressing the multifaceted aspects of Clostridium difficile infection, we can strive towards a future where CDI no longer poses a significant threat to public health. A comprehensive approach encompassing strategic preventive strategies, meticulous surveillance, and an unwavering commitment to patient safety will pave the way for a healthier and safer healthcare system for all individuals. It is imperative that we remain steadfast in our efforts to eliminate CDI and safeguard the well-being of patients within healthcare environments. By taking these collective steps, we can forge a path towards a future free from the burden of Clostridium difficile infection. (Negrut *et al*. 2020) (Davies *et al*. 2020) (Song *et al*. 2020) (Keffer, 2021) (Sumon *et al*. 2020) (Gupta and Ananthakrishnan 2021).

5.7 Klebsiella pneumoniae

Klebsiella pneumoniae is a medically significant bacteria species that is commonly found in hospitals worldwide. According to the comprehensive study conducted by Borg *et al* (2006), Klebsiella was identified as the most prevalent genus. While K. pneumoniae was discovered in various regions, it appears to have a higher prevalence in Europe compared to other parts of the world. The wide distribution of this bacterium can be attributed to its numerous adaptive characteristics, with one notable example being its ability to produce acids and persist in diverse materials. However, K. pneumoniae is notorious for its resistance to multiple antibiotics, posing a significant challenge in the healthcare setting. The importance of this bacterium lies in its capability to be shed from the fecal matter of colonized or carrying patients, resulting in a concentration of 106-108-MCAS (multi-cellular aggregated structure) per gram. This high rate of bacterial production, combined with Klebsiella's prolonged survival in the environment, often leads to extensive bacterial colonization. Consequently, it significantly complicates cleaning procedures and makes it more difficult to eliminate reservoirs of infection during an extended outbreak. Patients who become colonized or infected with K. pneumoniae may experience prolonged hospital stays that disrupt the regular activities of healthcare facilities, particularly if the behavior and reproduction of the pathogen contribute to an outbreak. Klebsiella pneumoniae is found across a wide range of ecological habitats, and its transmission is influenced by multiple factors. Notably, large-scale outbreaks attributable to specific clones of K. pneumoniae are not uncommon. With regards to infection control, Klebsiella pneumoniae necessitates the implementation of various precautions. These include standard precautions, contact precautions, airborne care, hand hygiene, and strict isolation protocols. Patients who are under ventilatory support pose a high-risk situation for infection control, demanding continuous monitoring and adherence to appropriate precautions. As a general recommendation, a ventilated patient from a K. pneumoniae-positive room should ideally be transferred to a different room that has not been previously occupied by a K. pneumoniae-infected patient. Alternatively, during shift changes, the patient can be temporarily moved to facilitate the airing and disinfection of the room. For maximum safety, it is advisable for patients with burns to wear fresh gowns and gloves, while healthcare providers should rigorously comply with infection control measures. This includes the thorough disinfection of contact equipment, such as stethoscopes and containers. Moreover, it is vital to establish regular surveillance and monitoring of antibiotic resistance patterns in K. pneumoniae strains to inform appropriate treatment strategies. Strengthening infection control practices at all levels of healthcare is of paramount importance to effectively mitigate the spread and impact of K. pneumoniae infections. It should be noted that in recent years, there has been a growing concern about the emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP). This specific strain has developed resistance to carbapenem antibiotics, which are considered the last line of defense against multi-drug resistant bacterial infections. The rise of CRKP poses an even greater threat to public health, as it severely limits treatment options and increases the risk of mortality. To combat this problem, stringent infection control measures, along with the development of new and effective antimicrobial agents, are necessary. In conclusion, Klebsiella pneumoniae is an important bacteria species that poses significant challenges in the healthcare setting. Its resistance to multiple antibiotics, ability to colonize and persist in the environment, and propensity for causing large-scale outbreaks highlight the need for strong infection control measures. By implementing appropriate precautions, conducting regular surveillance, and developing new treatment strategies, we can effectively mitigate the spread and impact of K. pneumoniae infections, ultimately improving patient outcomes and preventing the emergence of drug-resistant strains. (Dong *et al*., 2022) (Rolbiecki *et al*. 2024) (Rawy *et al*. 2020) (Galarde-López *et al*. 2022) (Tanni *et al*., 2021) (Wang *et al*. 2020) (Osman *et al*. 2021).

5.8 Methicillin-resistant Staphylococcus aureus (MRSA)

5. 8. Methicillin-resistant Staphylococcus aureus (MRSA) is a highly adaptable, invasive, and dangerous microbe to come into contact with while in a hospital setting. Its ability to resist methicillin, as well as a wide variety of antibiotics, makes it a formidable organism that can become multi-drug resistant. In fact, S. aureus has showcased its ability to develop resistance to every commercially available antibiotic used to treat it, including penicillin, methicillin, vancomycin, and linezolid. Although the development of resistance to newer drugs is slower, it still poses a significant threat. This pathogen has been found in almost every environment it has been exposed to and has the capability of infecting virtually any tissue it can reach. MRSA is more commonly associated with infections acquired in a healthcare setting, accounting for nearly 60% of cases, compared to only 19% for antibiotic-sensitive S. aureus. Its presence can delay the initiation of antibiotic therapy

by an average of 3. 14 days. Additionally, MRSA frequently leads to prolonged hospitalization, extended length-of-stay, and readmission. It also increases the likelihood of developing multiple sites of infection, metastatic or second-site infections, and the need for more invasive surgical procedures to manage the infection. The ease of transmission between individuals, coupled with its virulence, often results in the rapid spread of MRSA among sick and immunocompromised patients, leading to higher mortality rates. In the United States alone, MRSA is estimated to cause hundreds of thousands of hospital-acquired infections each year. A comprehensive study investigating bloodstream infections among outpatients in the U. S. revealed that, on average, 32% of these infections were attributed to MRSA. The prevalence of infections caused by this bacterial strain ranged from 10% to as high as 60%. The presence of MRSA in the bloodstream was associated with longer hospital stays, and patients infected with MRSA experienced more rapid mortality compared to those infected with methicillin-sensitive S. aureus. Furthermore, research indicates that approximately 40-50% of patients discharged from a hospital with an MRSA infection do not survive beyond one year, and shockingly, about 1 in 5 individuals with this condition succumb while still hospitalized. These distressing statistics highlight the severe impact of MRSA infections on both short-term and long-term patient outcomes. MRSA poses not only a significant burden on healthcare systems but also a grave threat to public health. It is imperative for medical professionals to implement strict infection control measures to prevent the spread of MRSA and develop effective strategies to combat this resilient and life-threatening pathogen. Methicillin-resistant Staphylococcus aureus (MRSA) is an extremely troublesome and menacing microorganism that poses a significant risk when encountered in a hospital environment. With its ability to withstand methicillin and a wide range of antibiotics, this microbe has acquired the capacity to become resistant to multiple drugs, making it an extremely formidable adversary. It is worth noting that S. aureus has proven its resilience by developing resistance against every commercially available antibiotic designed to combat it, starting from penicillin all the way to methicillin, vancomycin, and linezolid. Although the process of resistance development to new medications may be slower, the threat it poses remains undeniably substantial. This pathogenic bacterium has been discovered in almost every place it has been exposed to, and once it infiltrates the body, it can infect virtually any tissue it reaches. In the realm of healthcare-associated infections, MRSA is more commonly implicated, accounting for a staggering 60% of cases, while the antibiotic-sensitive strain of S. aureus constitutes only 19% of infections. When MRSA is present, the initiation of antibiotic treatment can be delayed by an average of 3. 14 days, and its consequences go far beyond that. Prolonged hospitalization, extended length-of-stay, and the likelihood of experiencing multiple infection sites, metastatic or secondary infections, as well as the need for more complex surgical interventions to manage the infection all become more probable in the presence of MRSA. The ease with which MRSA spreads among sick and immunocompromised patients, combined with its high level of virulence, leads to its rapid dissemination and subsequently elevated mortality rates. In the United States, MRSA is responsible for a considerable number of hospital-acquired infections, reaching hundreds of thousands annually. A comprehensive study conducted on outpatients in the U. S. demonstrated that, on average, 32% of bloodstream infections were attributed to MRSA. The prevalence of infections caused by this strain of bacteria ranged from a concerning 10% to an alarming 60%. The presence of MRSA in the bloodstream has been linked to longer hospital stays, and patients infected with MRSA face a faster mortality rate compared to those who succumb to methicillin-sensitive S. aureus. Shockingly, research indicates that approximately 40-50% of patients discharged from a hospital following an MRSA infection do not survive beyond one year, and even more disturbingly, about 1 in 5 individuals with this condition meet their demise while still hospitalized. These disconcerting figures highlight the severe and far-reaching consequences of MRSA infections on both short-term and long-term patient outcomes. The burden this resilient and life-threatening pathogen places on healthcare systems is immense, and its existence constitutes a grave menace to public health. Therefore, it is absolutely vital for medical professionals to enforce strict infection control measures in order to impede the spread of MRSA and to develop effective strategies to counteract this dangerous pathogen. (Tsouklidis *et al*., 2020) (Preeja *et al*., 2021) (Aljeldah, 2020) (Nandhini *et al*. 2022) (Moghaddam *et al*. 2022) (Alghamdi *et al*. 2023) (Mazi *et al*. 2020) (Dehghani and Karmostaji2022) (Mkhize *et al*. 2021) (Argudín *et al*. 2021).

5.9 Vancomycin-resistant Enterococci (VRE)

5. 9. Vancomycin-Resistant Enterococci (VRE) Vancomycin-resistant enterococci (VRE) are a significantly prevalent and concerning bacterial species found within the confines of hospitals around the world. Their existence poses a substantial and immediate threat to patient health due to their remarkably high rates of resistance and their persistent and tenacious nature. It is of paramount importance to acknowledge and recognize that more than 90% of VRE cases can be attributed to Enterococcus faecium, rather than *Enterococcus faecalis*, emphasizing the prevalent nature of this particular

strain. It is disheartening to note that these enterococci strains inherently possess an insurmountable resistance to penicillin and cephalosporin antibiotics, rendering standard treatment protocols devoid of effectiveness and leaving patients in a disheartening state of vulnerability. However, there is a glimmer of hope on the horizon, as certain vancomycin formulations available on the market have shown promising potential in combating enterococcal infections, although the relentless emergence of vancomycin-resistant strains globally poses a significant and formidable challenge to medical professionals and researchers alike. The emergence and prevalence of severe and fatal enterococcal infections in numerous countries further highlight and accentuate the utmost urgency in addressing the omnipresence and prevalence of VRE. Apart from the concerning and detrimental impact VRE has on the health and well-being of patients, it is worth noting that VRE has the capacity to persist and linger in the hospital environment for seemingly endless periods of time, consequently resulting in a substantial and exponential increase in infection management costs and a compromising compromise to overall patient safety and welfare. The management and control of enterococcal infections are complex and multifaceted matters, as they significantly contribute to the colossal and staggering expenses that are unapologetically associated with modern medical treatments. Furthermore, VRE presents formidable obstacles to the crucial and indispensable aspect of infection control within healthcare settings, given its persistent ability to survive on frequently touched and utilized surfaces, ensuring that its presence is a looming and ever-present threat. It is unfortunate but crucial to recognize that certain individuals face a disproportionately higher risk of colonization and infection by VRE. Those who find themselves in dire and prolonged situations within the intensive care unit (ICU), reside in long-term care facilities, or have underlying and pre-existing medical conditions are particularly vulnerable and susceptible. The necessity to prevent the spread and transmission of VRE from the hospital environment, as well as from infected or colonized patients, remains the utmost priority and a foundational tenet in ensuring the overall safety, well-being, and rapid recovery of patients. Therefore, it is absolutely vital to implement comprehensive and thorough routine infection control procedures within healthcare facilities, reinforcing the significance and efficacy of employing meticulous and precise sterilization measures for all medical devices, especially those that are reused and cannot simply be disposed of. By bearing this crucial responsibility in mind and exercising extreme caution and diligence when handling these reusable medical devices, healthcare professionals play an invaluable and pivotal role in successfully averting and preventing the transmission of VRE, and ultimately safeguarding and preserving the overall health, dignity, and well-being of every patient under their care. (Ayobami *et al*. 2020) (López-Luis *et al*. 2021) (Rios *et al*. 2020) (Zhou *et al*. 2020) (Olearo *et al*. 2021) (Werner *et al*. 2020) (O'Toole *et al*. 2023).

5.10 Carbapenem-resistant Enterobacteriaceae (CRE)

Carbapenem-Resistant Enterobacteriaceae (CRE) Enterobacteriaceae, an expansive family of bacteria, have an intricate relationship with humans and animals, oftentimes existing in peaceful symbiosis. However, within this family, there are a few notorious members that have the potential to cause harm and pose a significant threat to health. Particularly within healthcare institutions, the presence of Acinetobacter, Pseudomonas, and certain Enterobacteriaceae strains can result in catastrophic consequences, inflicting severe harm and, alarming enough, leading to deadly infections at a concerning frequency. Historically, carbapenems have been the go-to medications for effectively combating severe infections caused by Enterobacteriaceae. Yet, the emergence of "Carbapenem-Resistant Enterobacteriaceae" (CRE) has drastically escalated the urgency of the situation, as these bacteria represent a paramount healthcare-associated species. An alternative way to identify this formidable adversary is through the acronym "CPE," which has gained notable prominence. Carbapenems, classified as a broad-spectrum antibiotics, are specifically utilized in the treatment of challenging infections that have proved resistant to multiple drugs, earning the label "multidrug-resistant (MDR) " pseudomonads. However, CPE distinguishes itself as a menacing bacteria due to its ability to circumvent the effects of numerous medication types. It is crucial to highlight that, with prompt identification, most strains of CRE can be mitigated or successfully treated. This favorable outcome can be achieved when both the infected patient and all individuals who have had exposure to the bacteria diligently adhere to the established guidelines on disease control and prevention. Nonetheless, there exists the potential for CRE to spread rapidly throughout healthcare settings, evading any attempts at containment and facilitating the development of harmful, untreatable infections. The presence of CRE patients not only exerts a direct impact on healthcare facilities but also profoundly influences the surrounding communities, leaving an indelible impression. (Gao *et al*. 2022) (Jean *et al*. 2022) (Zhou *et al*. 2021) (Chen *et al*. 2021) (Predic *et al*. 2020) (Guo *et al*. 2022).

5.11 Extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae

Given the vast array of microbial compositions and the myriad variations in bacterial structures, nosocomial pathogens exhibit significant divergence from the members of the normal human flora. Connecting any particular species or strain of microorganism to a specific infection is an exceedingly intricate process that is only in its nascent stages. Nevertheless, it appears reasonable to focus primarily on a specific group of bacteria that are responsible for a substantial number of nosocomial infections and are demonstrating an escalating resistance to antibiotics. These bacteria belong to the Enterobacteriaceae family, which possess an extensive spectrum β-lactamase (ESBL) resistance mechanism. This segment encompasses 11 primary subcategories, providing pertinent information, categorizations, an overview, and clinical significance. Technically, the appropriate term should encompass resistance mechanisms of these bacteria, which are significantly more intricate. These bacteria exhibit highly variable reactions with conventional bacterial identification methods, with as many as 80 associated mechanisms currently posing challenges in practical settings. Furthermore, the phrase "ESBL-producing Enterobacteriaceae" more accurately reflects the clinical importance of identifying such species in laboratory settings, as the term implies considerations for treatment related to all ESBL resistance mechanisms. Hence, the term employed in this chapter solely signifies the production of enzymes that confer resistance to penicillins and cephems, unless specifically indicated otherwise. ESBLs that exhibit heightened activity against cephamycins and/or carbapenems are designated as Cephamycinase and carbapenemase producers, respectively. (Anju *et al*. 2020) (Dougnon *et al*. 2020) (Moxley, 2022) (Idrees *et al*., 2021).

Chapter - 6

Factors Contributing to the Prevalence of Bacteria in Hospitals

Factors contributing to the prevalence of the bacteria species in hospitals Several factors contribute to the prevalence of the most common species of this genus in the hospital environment. These include transmission through water sources, a transient yet predominant presence in the hospital environment, and the ability to survive and multiply in a variety of conditions, especially in biofilms and surfaces in many hospital wards. For instance, E. cloacae infections have frequently been linked to the use of contaminated fluids, such as intravenous solutions, water-borne nosocomial clonal outbreaks, or treatment with contaminated equipment such as ventilators or nebulizers. This bacterium has also been isolated from the hands of health workers. On the other hand, Klebsiella spp. are known as commensals of humans and animals and can be isolated from a variety of environmental sources, especially natural environments. K. pneumoniae and K. oxytoca have been mainly suggested to be well adapted to hospital and clinical settings and are most frequently associated with urinary and respiratory tract infections in immunocompromised individuals. Furthermore, which species of bacteria are most commonly found at inpatient healthcare institutions largely depends on the clinical ward. In general, Staphylococcus spp. (mostly Staphylococcus epidermidis), followed by Klebsiella pneumoniae and Proteus mirabilis, are the most prevalent microorganisms in the inpatient healthcare unit. Of the most frequently detected microorganisms, those from the genera Acinetobacter, Enterobacter, Klebsiella, Pseudomonas, and Serratia are often seen to be multi-drug resistant and show the potential to cause outbreaks in healthcare units. The occurrence of many of these potentially pathogenic bacteria can be linked to both the built and social environments in healthcare units, especially the presence of immunocompromised patients as well as the broad interaction between patients, visitors, and healthcare staff in the harsh environment of an acute care, high trauma general hospital. Numerous factors contribute to the prevalence of the most common species of bacteria in the hospital environment. These factors encompass a wide range of aspects that contribute to the transmission, survival, and growth of bacteria within healthcare settings. One of the primary factors is the transmission of bacteria through water sources. Bacteria can easily spread through contaminated water, leading to infections in individuals who come into contact with it. Additionally, the transient yet predominant presence of bacteria within hospitals plays a significant role in their prevalence. These bacteria have the ability to survive and multiply in various conditions, particularly in biofilms and on surfaces found in different hospital wards. For example, E. cloacae infections have often been linked to the use of contaminated fluids, such as intravenous solutions. The presence of this bacterium in these fluids can lead to infections in patients. Furthermore, water-borne nosocomial clonal outbreaks, as well as the use of contaminated equipment such as ventilators and nebulizers, have been associated with E. cloacae infections. It is worth noting that this bacterium has also been isolated from the hands of healthcare workers, highlighting the importance of hand hygiene in preventing the spread of bacteria. On the other hand, Klebsiella spp. are known as commensals of both humans and animals, meaning they naturally inhabit the bodies of these organisms without causing harm. They can be found in various environmental sources, especially natural environments. However, certain species of Klebsiella, such as K. pneumoniae and K. oxytoca, have been found to be well adapted to hospital and clinical settings. These particular species are frequently associated with urinary and respiratory tract infections, particularly in individuals with compromised immune systems. The prevalence of bacteria in inpatient healthcare institutions greatly depends on the specific clinical ward. In general, Staphylococcus spp., with Staphylococcus epidermidis being the predominant species, followed by Klebsiella pneumoniae and Proteus mirabilis, are the most commonly found microorganisms in these healthcare units. These bacteria can cause various infections and are a significant concern within healthcare settings. Among the frequently detected microorganisms, those from the genera Acinetobacter, Enterobacter, Klebsiella, Pseudomonas, and Serratia are often multi-drug resistant. This means they are unaffected by multiple types of antibiotics, making them difficult to treat. Additionally, these bacteria have the potential to cause outbreaks within healthcare units, posing a threat to patients and healthcare staff alike. The occurrence of many of these potentially pathogenic bacteria can be attributed to both the built and social environments within healthcare units. Such environments create conditions that are conducive to the growth and spread of bacteria. The presence of immunocompromised patients, who have weakened immune systems, increases the risk of infections caused by these bacteria. Furthermore, the close interaction between patients, visitors, and healthcare staff in the challenging environment of an acute care, high trauma general hospital contributes to the transmission and prevalence of bacteria. In conclusion, understanding the factors that contribute to the prevalence of bacteria within hospitals is essential for effective infection control and prevention strategies. By addressing the transmission, survival, and growth of bacteria in healthcare settings, healthcare institutions can work towards creating safer environments for patients, visitors, and healthcare staff. (Girlich *et al*. 2021) (Salimiyan *et al*. 2020) (Mullié *et al*. 2022) (Gekenidis *et al*., 2020) (Jung *et al*. 2020) (Praja *et al*. 2021) (Marchiani *et al*. 2021).

Chapter - 7

Antibiotic Resistance and Hospital-Acquired Infections

Antibiotic resistance and hospital-acquired infections significantly increase morbidity and contribute to mortality rates because they are often endogenous strains, rendering them more resistant to antibiotics. Additionally, the risk factor of invasive medical devices increases the severity of the infection, and they are a frequent target of nosocomial infections, with two-thirds of blood infections acquired through central venous catheters (CVCs). Unfortunately, if a patient's infection is caused by a multidrug-resistant bacteria, not only is their length of hospitalization longer, and therefore more expensive, but their chance of serious adverse events and subsequent penicillin treatment failure is also increased. Antibiotic or antimicrobial resistance is generally a major problem in healthcare, but poses a significant risk for hospital inpatients in particular. If a patient is admitted in an emergency situation, that is, to patients in an immunosuppressed state who are very vulnerable to infections, then anti-infective drugs may be administered empirically due to a lack of background patient information. If these pathogens are multidrug-resistant, or if the infection is severe, these treatments would, ideally, be intravenous. Often, these are older and less harmful agents, due to their potential for early use as empiric therapy. Thus, it is important to appreciate what organisms are involved in this population when considering possible origin organisms frequent causes of intra-hospital bloodstream infection and to be aware of the agents to be considered when treating these infections. In addition, it is crucial to implement stringent infection control measures, such as proper hand hygiene, appropriate use of personal protective equipment, and regular disinfection of medical equipment and surfaces. Moreover, surveillance systems should be in place to monitor the prevalence and patterns of antibiotic resistance in healthcare facilities, allowing for prompt identification and response to outbreaks. Education and training programs for healthcare professionals should also be prioritized to ensure proper prescribing and management of antibiotics, as well as the promotion of responsible antibiotic use among patients. Collaborative efforts between healthcare providers, researchers, policymakers, and the public are essential in combating antibiotic resistance and reducing the burden of hospital-acquired infections. By working together, we can safeguard the effectiveness of antibiotics and protect the health of patients in the hospital setting. Being fully aware of the challenges posed by resistant strains, healthcare institutions must devise effective strategies to control the spread of infections to limit the impacts on morbidity and mortality rates. This includes the development of strict protocols and guidelines for infection prevention and control, regular monitoring of antimicrobial resistance patterns, ensuring timely and accurate identification of infections, and implementing appropriate treatment strategies. Additionally, research and development in the field of antibiotic discovery and alternative antimicrobial therapies must be prioritized to provide new weapons in the fight against antibiotic resistance. By actively addressing these issues, healthcare facilities can play a crucial role in minimizing the consequences of antibiotic resistance and improving patient outcomes. (Hussein2022) (Church & McKillip, 2021) (Bakhtiyari *et al*. 2024) (Chinemerem *et al*. 2022) (Di *et al*. 2021) (Owusu, 2020) (Almatroudi, 2022).

Chapter - 8

Preventive Measures and Infection Control in Hospitals

A significant number of federally funded programs implemented worldwide are dedicated to implementing preventive measures and infection control protocols within hospital settings. These comprehensive programs aim to effectively eliminate or drastically diminish the occurrence of bacterial species that pose a high risk of infection to vulnerable patients. In the United States, these species primarily consist of the following eight common types: Clostridium difficile, various strains of Clostridium spp., *Enterococcus faecalis*, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Notably, alterations in the relative abundance of these prevalent bacteria species frequently manifest initially amongst adult patients receiving care in acute care settings, while older adults or individuals in long-term acute care (LTAC) settings are comparatively less affected. It is worth mentioning that a limited number of published studies have documented evidence of human outbreaks caused by antibiotic-resistant strains of bacteria within hospital environments. Nevertheless, the existing findings from recent therapeutic product initiatives, aimed at meticulously cataloging incidence data pertaining to such outbreaks in conjunction with patient placement, medical procedures, and the exposure of care team personnel, are subsequently summarized. Additionally, various interventions have been observed to yield desirable effects, such as the reduction or complete elimination of at-risk bacterial species. These interventions include, but are not limited to: (1) the implementation of infection control measures resulting in a noteworthy decrease in infection and mortality rates within the intensive care unit (ICU) setting—a protective effect that spans an average duration of 210 days for each respective intervention; (2) the implementation of hospital-wide measures leading to a reduction in infection rates caused by potentially prevalent bacterial species carrying antibiotic resistance genes; (3) the meticulous monitoring of outcomes stemming from intervention trials as part of an international humanitarian effort aimed at halting the ongoing outbreak of Lassa fever in Nigeria; (4) the establishment of improved control measures within countries located on the West coast of Africa to regulate the transmission rates of Lassa fever, which surpass those observed in Nigeria. These measures have proven to be instrumental in curbing the spread of infectious diseases, ensuring the safety of patients, and enhancing the overall quality of healthcare systems worldwide. As global efforts continue to prioritize infection control and prevention, it is expected that further advancements and innovations will significantly contribute to the continuous improvement of hospital settings in combating bacterial infections and safeguarding public health. These advancements include increased research funding, advanced antimicrobial therapies, enhanced surveillance systems, and the development of novel vaccines and diagnostic tools. Through these collective efforts, the global healthcare community will ultimately achieve a higher level of preparedness and resilience against emerging infectious threats, ensuring the protection and well-being of individuals around the world. (Stefanini *et al*. 2020) (Szabó *et al*. 2022) (Valzano *et al*., 2024) (Pauter *et al*., 2020).

Chapter - 9

Future Trends and Research Directions

Based on the state of the art, we speculate that a reproducible and real-time rapid detecting model for hand hygiene, to enhance the compliance of infection control practice in healthcare settings, will become a hot topic in the near future by integrating such technologies as a biosensor, AIoT devices, and blockchain. From the perspective of hospital-built environment, monitoring the airborne bacterial communities in the hand hygiene (HH) area and their correlation with healthcare worker (HCW) numbers, indoor environment, and infection rate would be a further trend. With the advancement of microbial gene sequencing, new technologies have been widely used for infection control. Metagenomic Next Generation Sequencing (mNGS) has been widely used in the diagnosis and treatment of infectious diseases and is expected to be one of the new technologies for the molecular diagnosis of airborne bacterial infection. Apart from these, some studies demonstrate that airborne bacteria are important to alleviate Occupational Asthma (OA) in medical staff or ambulatory patients; they become an issue for exploring the relationship between infection and chronic diseases in the future. Bacterial contamination of the healthcare built environment, e. g., the floors, beds, and surfaces, is a principal infection reservoir and a moderator on the healthcare-associated infection (HAI). Deaths or disabilities resulting from infection could be catastrophic. This review summarized the most common types of bacterial species in isolation from hospital environments around the world. This study used the top 10 countries with the highest number of confirmed cases of coronavirus disease 2019 (COVID-19) to classify and review the common environmental microbial communities of intensive care unit (ICU) isolation scenarios. This study highlights differences in the dominant species of bacteria between the literature and different regions. A multidisciplinary approach should be used to distinguish the pathogenic bacteria and community structure in the microbial environment, and a diversity of treatment strategies based on the spatial distribution. It is necessary to build a pilot zone for clinical trials to explore the optimal disinfection solutions. It is crucial to devise comprehensive policies and guidelines to mitigate the risk of infections in healthcare settings, as even a single lapse in hand hygiene or inadequate disinfection strategies can lead to severe consequences. The integration of cutting-edge technologies such as biosensors, AIoT devices, and blockchain can revolutionize the field of infection control by providing real-time and reproducible detection of hand hygiene practices. These technologies can enable healthcare professionals to monitor airborne bacterial communities in the hand hygiene area, thereby correlating them with the number of healthcare workers, indoor environment conditions, and infection rates. Additionally, the advancements in microbial gene sequencing, particularly the use of Metagenomic Next Generation Sequencing (mNGS), hold great promise in the diagnosis and treatment of infectious diseases, including airborne bacterial infections. Furthermore, further research should explore the potential of airborne bacteria in alleviating Occupational Asthma (OA) in medical staff and ambulatory patients, as well as understanding their role in the development of chronic diseases. It is imperative to recognize that bacterial contamination in the healthcare built environment, such as floors, beds, and surfaces, serves as a major source of healthcare-associated infections (HAIs). Given the catastrophic consequences of infections resulting in deaths or disabilities, it is essential to identify and address the common types of bacterial species prevalent in hospital environments worldwide. This comprehensive understanding can enhance infection control measures and facilitate the development of targeted treatment strategies based on the spatial distribution of pathogenic bacteria and community structure in the microbial environment. Moreover, the establishment of pilot zones for clinical trials is crucial in uncovering optimal disinfection solutions. Thus, a multidisciplinary approach is necessary to navigate the complexities associated with microbial environments in healthcare settings and ensure effective infection control practices. By adopting such an approach along with the implementation of robust policies and guidelines, healthcare facilities can significantly reduce the risk of infections and safeguard the well-being of patients and healthcare workers. The integration of advanced technologies, including biosensors, AIoT devices, and blockchain, holds the potential to drive a paradigm shift in infection control by enabling real-time and reproducible hand hygiene detection. By leveraging these cutting-edge tools, healthcare practitioners can actively monitor airborne bacterial communities within hand hygiene areas, establishing correlations with variables such as healthcare worker population, indoor environmental conditions, and infection rates. Concurrently, the advent of microbial gene sequencing has paved the way for novel infection control techniques. Of particular note is the Metagenomic Next Generation Sequencing (mNGS), a method that has gained widespread application in diagnosing and treating infectious diseases, ultimately emerging as a promising tool for molecular airborne bacterial infection diagnosis. Beyond its diagnostic capabilities, the study of airborne bacteria presents intriguing prospects in the mitigation of Occupational Asthma (OA) for medical personnel and ambulatory patients, while also motivating investigations into the interplay between infections and chronic illnesses. It is crucial to acknowledge that the healthcare built environment encompasses critical sites of bacterial contamination, such as floors, beds, and various surfaces, often serving as primary reservoirs for healthcare-associated infections (HAIs). Given the catastrophic implications of infections leading to severe health complications or even mortality, it becomes paramount to comprehensively comprehend the prevalent bacterial species inhabiting hospital environments worldwide. Such an understanding can undoubtedly bolster infection control measures and facilitate the formulation of targeted treatment strategies utilizing the spatial distribution of pathogenic bacteria and community framework within microbial environments. Additionally, the establishment of pilot zones for clinical trials assumes utmost importance, as they can offer valuable insights into optimal disinfection solutions. Thus, navigating the intricacies of microbial landscapes within healthcare settings necessitates the seamless integration of multidisciplinary approaches, empowering healthcare organizations to deploy effective infection control practices. Implementing robust policies and guidelines assumes an equally crucial role, as even a solitary breach in hand hygiene or inadequate disinfection measures can have grave consequences, compromising the well-being of patients and healthcare practitioners alike. (Hassoun-Kheir *et al*. 2020) (Mancuso *et al*., 2021) (Urban-Chmiel *et al*. 2022) (Nguyen & Joshi, 2021) (Assefa & Amare, 2022) (Avershina *et al*., 2021) (Morris & Cerceo, 2020) (Hammoudi Halat & Ayoub Moubareck, 2020) (O'Toole, 2021) (Haque *et al*. 2020).

Conclusion

This essay demonstrates that bacterial species are prevalent and widely spread throughout hospitals. Epidemics originating from bacterial contamination are effectively facilitated in hospital grounds. Not only are the odds of similar unwanted incidents increasing substantially due to bacteria living within hospital settings, but it may also adversely affect patient health if not properly addressed in the caregiving process. Consequently, the release of bacteria into the environment worldwide is a concern for those working to prevent contamination. The management of hospital strains of bacteria will improve with a detailed understanding of the routine forms and potential areas of expansion for the infectivity of these microbes.

For washing and disinfecting surgical regions, many of the spillages are linked cautiously to several species. A strategic management plan would achieve control of bacterial and environmental diversity by focusing on major bacterial species. Additionally, a reduction in outbreaks caused by prevalent bacterial species at community occasions, including respite homes, can be achieved by limiting bacterial contamination at mess hall events. A detailed understanding of bacterial communities can also support the preemptive diagnosis and treatment of those responsible. Moreover, an emphasis on the most common bacteria in hospitals will allow for a complete shift in the methodologies of the laboratory's risk evaluation department and clinical diagnostic methods. In conclusion, the examination of diverse pathogenic strains of bacteria in hospital grounds serves two purposes. It helps predict which surveillance procedures are necessary to control these bacterial strains and highlights the need for evolution in these procedures.

References

1. Aqel, H., Sannan, N., & Foudah, R. (2023). From Hospital to Community: Exploring Antibiotic Resistance and Genes Associated with Virulence Factor Diversity of Coagulase-Positive Staphylococci. Antibiotics. mdpi. com
2. Eticha, T., Tamire, T., & Gelgelu, T. B. (2022). Antibiotic susceptibility pattern of coagulase positive Staphylococcus aureus isolated from patients admitted at Tikur Anbessa specialized Hospital, Addis Ababa. Health Science Journal. [HTML]
3. Abdeen, E. E., Mousa, W. S., Abdelsalam, S. Y., Heikal, H. S., Shawish, R. R., Nooruzzaman, M.,... & Abdeen, A. (2021). Prevalence and characterization of coagulase positive Staphylococci from food products and human specimens in Egypt. Antibiotics, 10(1), 75. mdpi.com
4. Salamandane, A., Oliveira, J., Coelho, M., Ramos, B., Cunha, M. V., Malfeito-Ferreira, M., & Brito, L. (2022). Enterotoxin-and antibiotic-resistance-encoding genes are present in both coagulase-positive and coagulase-negative foodborne Staphylococcus strains. Applied Microbiology, 2(2), 367-380. mdpi.com
5. Becker, K., Both, A., Weißelberg, S., Heilmann, C., & Rohde, H. (2020). Emergence of coagulase-negative staphylococci. Expert review of anti-infective therapy, 18(4), 349-366. [HTML]
6. Jibu, R. M., Geetha, R. V., & Lakshmi, T. (2020). Isolation, detection and molecular characterization of Staphylococcus aureus from Postoperative Infections. Journal of Pharmaceutical Research International, 63-7. academia.edu
7. Petrillo, F., Pignataro, D., Di Lella, F. M., Reibaldi, M., Fallico, M., Castellino, N.,... & Boccia, G. (2021). Antimicrobial susceptibility patterns and resistance trends of staphylococcus aureus and coagulase-negative staphylococci strains isolated from ocular infections. Antibiotics, 10(5), 527. mdpi.com
8. Abusleme, F., Galarce, N., Quezada-Aguiluz, M., Iragüen, D., & González-Rocha, G. (2022). Characterization and antimicrobial susceptibility of coagulase-positive Staphylococcus isolated in a veterinary teaching hospital in Chile. Revista Argentina de

Microbiologia, 54(3), 192-202. sciencedirect.com

9. O'Toole, R. F. (2021). The interface between COVID-19 and bacterial healthcare-associated infections. Clinical Microbiology and Infection. sciencedirect.com

10. Voidazan, S., Albu, S., Toth, R., Grigorescu, B., Rachita, A., & Moldovan, I. (2020). Healthcare associated infections—a new pathology in medical practice?. International journal of environmental research and public health, 17(3), 760. mdpi.com

11. Weiner-Lastinger, L. M., Abner, S., Edwards, J. R., Kallen, A. J., Karlsson, M., Magill, S. S.,... & Dudeck, M. A. (2020). Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infection Control & Hospital Epidemiology, 41(1), 1-18. nih.gov

12. Jernigan, J. A., Hatfield, K. M., Wolford, H., Nelson, R. E., Olubajo, B., Reddy, S. C.,... & Baggs, J. (2020). Multidrug-resistant bacterial infections in US hospitalized patients, 2012–2017. New England Journal of Medicine, 382(14), 1309-1319. nejm.org

13. Nelson, R. E., Hyun, D., Jezek, A., & Samore, M. H. (2022). Mortality, length of stay, and healthcare costs associated with multidrug-resistant bacterial infections among elderly hospitalized patients in the United States. Clinical Infectious Diseases, 74(6), 1070-1080. oup.com

14. Mackuľak, T., Cverenkárová, K., Vojs Staňová, A., Fehér, M., Tamáš, M., Škulcová, A. B.,... & Bírošová, L. (2021). Hospital wastewater—source of specific micropollutants, antibiotic-resistant microorganisms, viruses, and their elimination. Antibiotics, 10(9), 1070. mdpi.com

15. Weiner-Lastinger, L. M., Abner, S., Benin, A. L., Edwards, J. R., Kallen, A. J., Karlsson, M.,... & Dudeck, M. A. (2020). Antimicrobial-resistant pathogens associated with pediatric healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infection Control & Hospital Epidemiology, 41(1), 19-30. nih.gov

16. Nelson, R. E., Hatfield, K. M., Wolford, H., Samore, M. H., Scott, R. D., Reddy, S. C.,... & Baggs, J. (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clinical Infectious Diseases, 72(Supplement_1), S17-S26. [HTML]

17. Tsouklidis, N., Kumar, R., Heindl, S. E., Soni, R., & Khan, S. (2020). … the fight against resistance: hospital-acquired methicillin-resistant Staphylococcus aureus vs. community-acquired methicillin-resistant Staphylococcus …. Cureus. nih.gov

18. Grasselli, G., Scaravilli, V., Mangioni, D., Scudeller, L., Alagna, L., Bartoletti, M.,... & Bandera, A. (2021). Hospital-acquired infections in critically ill patients with COVID-19. Chest, 160(2), 454-465. chestnet.org

19. Sevin, T., Daniau, C., Alfandari, S., Piednoir, E., Dumartin, C., Blanchard, H.,... & Le Vu, S. (2021). Patterns of antibiotic use in hospital-acquired infections. Journal of Hospital Infection, 114, 104-110. sciencedirect.com

20. Pickens, C. I., & Wunderink, R. G. (2022, April). Methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia/ventilator-associated pneumonia. In Seminars in respiratory and critical care medicine (Vol. 43, No. 02, pp. 304-309). Thieme Medical Publishers, Inc.. nih.gov

21. Samia, N. I., Robicsek, A., Heesterbeek, H., & Peterson, L. R. (2022). Methicillin-resistant staphylococcus aureus nosocomial infection has a distinct epidemiological position and acts as a marker for overall hospital-acquired infection …. Scientific reports. nature.com

22. Boussion, K., Zappella, N., Grall, N., Ribeiro-Parenti, L., Papin, G., & Montravers, P. (2021). Epidemiology, clinical relevance and prognosis of staphylococci in hospital-acquired postoperative intra-abdominal infections: an observational study in intensive care unit. Scientific Reports, 11(1), 5884. nature.com

23. Janda, J. M. & Abbott, S. L. (2021). The Changing Face of the Family Enterobacteriaceae (Order: “Enterobacterales”) : New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and …. Clinical microbiology reviews. nih.gov

24. Maina, S. M. (2020). Isolation of Bacteria and Prevalence of Resistant Genes in Isolates from Hospital Waste and Surfaces and its Management in Hospitals in Kenya. jkuat.ac.ke

25. Lloyd, R. V. (2023). Bacteriology. Pathology: Historical and Contemporary Aspects. [HTML]

26. Barlandas-Quintana, E. A., & Martinez-Ledesma, J. E. (2020, December). Detection of carbapenems resistant k-mer sequences in

bacteria of critical priority by the world health organization (pseudomonas aeruginosa and acinetobacter baumannii). In 2020 7th International Conference on Internet of Things: Systems, Management and Security (IOTSMS) (pp. 1-8). IEEE. [HTML]

27. Bispo, P. J. M., Sahm, D. F., & Asbell, P. A. (2022). A systematic review of multi-decade antibiotic resistance data for ocular bacterial pathogens in the United States. Ophthalmology and Therapy. springer.com

28. Peng, Z., Wang, X., Huang, J., & Li, B. (2024). Pathogenic Escherichia coli. Molecular Medical Microbiology. researchgate.net

29. Puvača, N. & de Llanos Frutos, R. (2021). Antimicrobial Resistance in Escherichia coli Strains Isolated from Humans and Pet Animals. Antibiotics. mdpi.com

30. Riley, L. W. (2020). Distinguishing pathovars from nonpathovars: Escherichia coli. Microbiology spectrum. asm.org

31. EFSA Biohaz Panel, Koutsoumanis, K., Allende, A., Alvarez‐Ordóñez, A., Bover‐Cid, S., Chemaly, M.,... & Bolton, D. (2020). Pathogenicity assessment of Shiga toxin‐producing Escherichia coli (STEC) and the public health risk posed by contamination of food with STEC. Efsa Journal, 18(1), e05967. wiley.com

32. Aworh, M. K., Kwaga, J. K., Hendriksen, R. S., Okolocha, E. C., & Thakur, S. (2021). Genetic relatedness of multidrug resistant Escherichia coli isolated from humans, chickens and poultry environments. Antimicrobial Resistance & Infection Control, 10, 1-13. springer.com

33. Odonkor, S. T. & Mahami, T. (2020). Escherichia coli as a Tool for Disease Risk Assessment of Drinking Water Sources. International Journal of Microbiology. wiley.com

34. Panel, E. B., Koutsoumanis, K., Allende, A., Alvarez‐Ordónez, A., Bover‐Cid, S., Chemaly, M.,... & Bolton, D. (2020). Pathogenicity assessment of Shiga toxin‐producing Escherichia coli (STEC) and the public health risk posed by contamination of food with STEC. Efsa Journal. irta.cat

35. Zhang, S., Abbas, M., Rehman, M. U., Huang, Y., Zhou, R., Gong, S.,... & Cheng, A. (2020). Dissemination of antibiotic resistance genes (ARGs) via integrons in Escherichia coli: a risk to human health. Environmental Pollution, 266, 115260. [HTML]

36. Cheung, G. Y. C., Bae, J. S., & Otto, M. (2021). Pathogenicity and

virulence of Staphylococcus aureus. Virulence. tandfonline.com

37. Rungelrath, V. & DeLeo, F. R. (2021). Staphylococcus aureus, Antibiotic Resistance, and the Interaction with Human Neutrophils. Antioxidants & redox signaling. nih.gov

38. Park, S. & Ronholm, J. (2021). Staphylococcus aureus in agriculture: lessons in evolution from a multispecies pathogen. Clinical microbiology reviews. nih.gov

39. Algammal, A. M., Hetta, H. F., Elkelish, A., Alkhalifah, D. H. H., Hozzein, W. N., Batiha, G. E. S.,... & Mabrok, M. A. (2020). Methicillin-Resistant Staphylococcus aureus (MRSA) : one health perspective approach to the bacterium epidemiology, virulence factors, antibiotic-resistance, and zoonotic impact. Infection and drug resistance, 3255-3265. tandfonline.com

40. Pidwill, G. R., Gibson, J. F., Cole, J., Renshaw, S. A., & Foster, S. J. (2021). The role of macrophages in Staphylococcus aureus infection. Frontiers in immunology, 11, 620339. frontiersin.org

41. Hardy, B. L., Bansal, G., Hewlett, K. H., Arora, A., Schaffer, S. D., Kamau, E.,... & Merrell, D. S. (2020). Antimicrobial activity of clinically isolated bacterial species against Staphylococcus aureus. Frontiers in microbiology, 10, 2977. frontiersin.org

42. Clegg, J., Soldaini, E., McLoughlin, R. M., Rittenhouse, S., Bagnoli, F., & Phogat, S. (2021). Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies. Frontiers in immunology, 12, 705360. frontiersin.org

43. Benedict, J. (2023). Poisoned: the true story of the deadly *E. coli* outbreak that changed the way Americans eat. [HTML]

44. Todd, E. C. D. (2022). Overview on food safety in the Middle East. Food Safety in the Middle East. [HTML]

45. Long, J., Du, G., Chen, J., Xie, C., Xu, J., & Yuan, J. (2023). Bacteria and poisonous plants/fungi were the primary causative hazards of foodborne disease outbreaks: A five-year survey from Guangzhou, Guangdong. International Journal of Food Microbiology, 400, 110264. [HTML]

46. Warmate, D. & Onarinde, B. A. (2023). Food safety incidents in the red meat industry: A review of foodborne disease outbreaks linked to the consumption of red meat and its products, 1991 to 2021. International Journal of Food Microbiology. sciencedirect.com

47. Luu-Thi, H. & Michiels, C. W. (2021). Microbiological safety of ready-to-eat foods in hospital and university canteens in Hanoi, Vietnam. Journal of Food Protection. sciencedirect.com

48. Ehuwa, O., Jaiswal, A. K., & Jaiswal, S. (2021). Salmonella, Food Safety and Food Handling Practices. Foods. mdpi.com

49. Adefrash, K., Sharew, B., Amare, W., & Shibabaw, A. (2024). Bacterial foodborne illness and Escherichia coli O157: H7 strain infection among asymptomatic food handlers in Northeast Ethiopia: Implication for hygienic practices and mass-screening. Health Science Reports, 7(6), e2199. wiley.com

50. Masood, E., Hassanin, F., Abou EL-Roos, N., & Sabeq, I. I. (2024). Multidrug-resistant *E. coli* and Salmonella Isolated from Raw and Ready-to-Eat Meat Products, Raising the potential of Future Foodborne Illness and Treatment Challenges. Egyptian Journal of Veterinary Sciences, 56(3), 587-603. ekb.eg

51. Erdem, I., Yıldırım, I., Safak, B., Karaali, R., Erdal, B., Ardic, E.,... & Arar, C. (2022). A 5-year surveillance of healthcare-associated infections in a university hospital: a retrospective analysis. SAGE Open Medicine, 10, 20503121221091789. sagepub.com

52. Farzin, A., Rahman, M. M., & Mollika, F. A. (2023). Pseudomonas aeruginosa: The Alarming Pathogen of Hospital Acquired Infection. intechopen.com

53. Kontula, K. S., Skogberg, K., Ollgren, J., Järvinen, A., & Lyytikäinen, O. (2022). Early deaths associated with community-acquired and healthcare-associated bloodstream infections: a population-based study, Finland, 2004 to 2018. Eurosurveillance, 27(36), 2101067. eurosurveillance.org

54. Salmanov, A., Shchehlov, D., Svyrydiuk, O., Bortnik, I., Mamonova, M., Korniyenko, S.,... & Bondar, T. (2023). Epidemiology of healthcare-associated infections and mechanisms of antimicrobial resistance of responsible pathogens in Ukraine: a multicentre study. Journal of Hospital Infection, 131, 129-138. [HTML]

55. Spagnolo, A. M., Sartini, M., & Cristina, M. L. (2021). Pseudomonas aeruginosa in the healthcare facility setting. Reviews and Research in Medical Microbiology, 32(3), 169-175. lww.com

56. Haque, M., McKimm, J., Sartelli, M., Dhingra, S., Labricciosa, F. M., Islam, S.,... & Charan, J. (2020). Strategies to prevent healthcare-associated infections: a narrative overview. Risk management and

healthcare policy, 1765-1780. tandfonline.com

57. Ayobami, O., Willrich, N., Reuss, A., Eckmanns, T., & Markwart, R. (2020). The ongoing challenge of vancomycin-resistant Enterococcus faecium and *Enterococcus faecalis* in Europe: an epidemiological analysis of bloodstream infections. Emerging Microbes & Infections, 9(1), 1180-1193. tandfonline.com

58. Davis, E., Hicks, L., Ali, I., Salzman, E., Wang, J., Snitkin, E.,... & Foxman, B. (2020, January). Epidemiology of vancomycin-resistant Enterococcus faecium and *Enterococcus faecalis* colonization in nursing facilities. In Open Forum Infectious Diseases (Vol. 7, No. 1, p. ofz553). US: Oxford University Press. oup.com

59. López-Luis, B. A., Sifuentes-Osornio, J., Lambraño-Castillo, D., Ortiz-Brizuela, E., Ramírez-Fontes, A., Tovar-Calderón, Y. E.,... & Ponce-de-León, A. (2021). Risk factors and outcomes associated with vancomycin-resistant Enterococcus faecium and ampicillin-resistant *Enterococcus faecalis* bacteraemia: a 10-year study in a tertiary-care centre in Mexico City. Journal of Global Antimicrobial Resistance, 24, 198-204. sciencedirect.com

60. Lupia, T., Roberto, G., Scaglione, L., Shbaklo, N., De Benedetto, I., Scabini, S.,... & Corcione, S. (2022). Clinical and microbiological characteristics of bloodstream infections caused by Enterococcus spp. within internal medicine wards: a two-year single-centre experience. Internal and Emergency Medicine, 17(4), 1129-1137. springer.com

61. Herrera-Hidalgo, L., Fernández-Rubio, B., Luque-Márquez, R., López-Cortés, L. E., Gil-Navarro, M. V., & De Alarcón, A. (2023). Treatment of *Enterococcus faecalis* infective endocarditis: a continuing challenge. Antibiotics, 12(4), 704. mdpi.com

62. Uda, A., Shigemura, K., Kitagawa, K., Osawa, K., Onuma, K., Yan, Y.,... & Miyara, T. (2021). Risk factors for the acquisition of enterococcus faecium infection and mortality in patients with enterococcal bacteremia: a 5-year retrospective analysis in a tertiary care university hospital. Antibiotics, 10(1), 64. mdpi.com

63. Iancu, A. V., Arbune, M., Zaharia, E. A., Tutunaru, D., Maftei, N. M., Peptine, L. D.,... & Gurău, G. (2023). Prevalence and antibiotic resistance of enterococcus spp. : A retrospective study in hospitals of Southeast Romania. Applied Sciences, 13(6), 3866. mdpi.com

64. Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J.,

Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A.,... & Barrientos Fortes, T. (2020). Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics, 9(4), 205. mdpi.com

65. Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Tragiannidis, A. (2021). Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens. mdpi.com

66. Goldberg, J. A., Kumar, V., Spencer, E. J., Hoyer, D., Marshall, S. H., Hujer, A. M.,... & Bonomo, R. A. (2021). A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. European Journal of Medicinal Chemistry, 220, 113436. sciencedirect.com

67. Li, Y., Wang, B., Lu, F., Ahn, J., Zhang, W., Cai, L.,... & He, X. (2022). Synergistic inhibitory effect of polymyxin B in combination with ceftazidime against robust biofilm formed by Acinetobacter baumannii with genetic deficiency in AbaI/AbaR quorum sensing. Microbiology Spectrum, 10(1), e01768-21. asm.org

68. Yang, Y., Guo, Y., Yin, D., Zheng, Y., Wu, S., Zhu, D., & Hu, F. (2020). In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: results from China Antimicrobial Surveillance Network (CHINET) in 2018. Antimicrobial agents and chemotherapy, 65(1), 10-1128. asm.org

69. Shi, J., Cheng, J., Liu, S., Zhu, Y., & Zhu, M. (2024). Acinetobacter baumannii: an evolving and cunning opponent. Frontiers in Microbiology. frontiersin.org

70. Nguyen, M. & Joshi, S. G. (2021). Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review. Journal of applied microbiology. wiley.com

71. Negrut, N., Nistor-Cseppento, D. C., Khan, S. A., Pantis, C., Maghiar, T. A., Maghiar, O.,... & Bungau, S. (2020). Clostridium difficile infection epidemiology over a period of 8 years—a single centre study. Sustainability, 12(11), 4439. mdpi.com

72. Davies, K., Mawer, D., Walker, A. S., Berry, C., Planche, T., Stanley, P.,... & Wilcox, M. H. (2020, November). An analysis of Clostridium difficile environmental contamination during and after treatment for C difficile infection. In Open forum infectious diseases (Vol. 7, No. 11, p.

ofaa362). US: Oxford University Press. oup.com

73. Song, J., Cohen, B., Zachariah, P., Liu, J., & Larson, E. L. (2020). Temporal change of risk factors in hospital-acquired Clostridioides difficile infection using time-trend analysis. Infection Control & Hospital Epidemiology, 41(9), 1048-1057. researchgate.net

74. Keffer, S. (2021). The Epidemiology of Clostridioides Difficile in Nebraska-A Descriptive Study Between 2018-2020. unmc.edu

75. Sumon, Z. E., Lesse, A. J., Sellick, J. A., Tetewsky, S., & Mergenhagen, K. A. (2020). Temporal trends of inpatient C. difficile infections within the Veterans Health Administration hospitals: An analysis of the effect of molecular testing, time to testing, and mandatory reporting. Infection Control & Hospital Epidemiology, 41(1), 44-51. ymvkt. cn

76. Gupta, A., & Ananthakrishnan, A. N. (2021). Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therapeutic Advances in Gastroenterology, 14, 17562848211018654. sagepub.com

77. Dong, N., Yang, X., Chan, E. W. C., Zhang, R., & Chen, S. (2022). Klebsiella species: Taxonomy, hypervirulence and multidrug resistance. EBioMedicine. thelancet.com

78. Rolbiecki, D., Paukszto, Ł., Krawczyk, K., Korzeniewska, E., Sawicki, J., & Harnisz, M. (2024). Genomic and metagenomic analysis reveals shared resistance genes and mobile genetic elements in *E. coli* and Klebsiella spp. isolated from hospital patients and hospital wastewater at intra-and inter-genus level. International Journal of Hygiene and Environmental Health, 261, 114423. researchgate.net

79. Rawy, D. K., El-Mokhtar, M. A., Hemida, S. K., Askora, A., & Yousef, N. (2020). Isolation, characterization and identification of Klebsiella pneumoniae from assiut university hospital and sewage water in assiut governorate, Egypt. Assiut Univ J Botany Microbiol, 49(2), 60-76. ekb.eg

80. Galarde-López, M., Velazquez-Meza, M. E., Bobadilla-del-Valle, M., Carrillo-Quiroz, B. A., Cornejo-Juárez, P., Ponce-de-León, A.,... & Alpuche-Aranda, C. M. (2022). Surveillance of antimicrobial resistance in hospital wastewater: identification of carbapenemase-producing Klebsiella spp. Antibiotics, 11(3), 288. mdpi.com

81. Tanni, A. A., Hasan, M. M., Sultana, N., Ahmed, W., & Mannan, A. (2021). … of antibiotic resistance and associated genes in Klebsiella pneumoniae isolates: A clinical observational study in different hospitals

in Chattogram, Bangladesh. Plos one. plos.org

82. Wang, B., Pan, F., Wang, C., Zhao, W., Sun, Y., Zhang, T.,... & Zhang, H. (2020). Molecular epidemiology of Carbapenem-resistant Klebsiella pneumoniae in a paediatric hospital in China. International Journal of Infectious Diseases, 93, 311-319. sciencedirect.com

83. Osman, E. A., El-Amin, N. E., Al-Hassan, L. L., & Mukhtar, M. (2021). Multiclonal spread of Klebsiella pneumoniae across hospitals in Khartoum, Sudan. Journal of Global Antimicrobial Resistance, 24, 241-245. sciencedirect.com

84. Preeja, P. P., Kumar, S. H., & Shetty, V. (2021). Prevalence and Characterization of Methicillin-Resistant Staphylococcus aureus from Community- and Hospital-Associated Infections: A Tertiary Care Center Study. Antibiotics. mdpi.com

85. Aljeldah, M. M. (2020). Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) in Saudi Arabia: A Systematic Review.. Journal of Pure & Applied Microbiology. semanticscholar.org

86. Nandhini, P., Kumar, P., Mickymaray, S., Alothaim, A. S., Somasundaram, J., & Rajan, M. (2022). Recent developments in methicillin-resistant Staphylococcus aureus (MRSA) treatment: A review. Antibiotics, 11(5), 606. mdpi.com

87. Moghaddam, T. S., Namaei, M. H., Afshar, D., & Yousefi, M. (2022). High frequency of SCCmec type IV and multidrug-resistant SCCmec type I among hospital acquired methicillin-resistant Staphylococcus aureus isolates in Birjand Imam Reza Hospital, Iran. Iranian Journal of Microbiology, 14(1), 67. nih.gov

88. Alghamdi, B. A., Al-Johani, I., Al-Shamrani, J. M., Alshamrani, H. M., Al-Otaibi, B. G., Almazmomi, K., & Yusof, N. Y. (2023). Antimicrobial resistance in methicillin-resistant Staphylococcus aureus. Saudi journal of biological sciences, 30(4), 103604. sciencedirect.com

89. Mazi, W., Alshammari, F., Yu, J., Alam, M. J., Saeed, M., Alshaghdali, K., & Saeed, A. (2020). A descriptive analysis of PVL-positive multidrug-resistant Staphylococcus aureus in hospital-associated infections in Saudi Arabia. Bioinformation, 16(8), 586. nih.gov

90. Dehghani, T., & Karmostaji, A. (2022). Molecular and Phenotypic Characterization of Methicillin-Resistant Staphylococcus aureus in Community and Hospital Acquired Infections in Bandar Abbas. Infection Epidemiology and Microbiology, 8(3), 233-241. modares.ac.ir

91. Mkhize, S., Amoako, D. G., Shobo, C. O., Zishiri, O. T., & Bester, L. A. (2021). Genotypic and Phenotypic Characterizations of Methicillin-Resistant Staphylococcus aureus (MRSA) on Frequently Touched Sites from Public Hospitals in South Africa. International journal of microbiology, 2021(1), 6011045. wiley.com

92. Argudín, M. A., Deplano, A., Nonhoff, C., Yin, N., Michel, C., Martiny, D.,... & Hallin, M. (2021). Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium. European journal of clinical microbiology & infectious diseases, 40(11), 2335-2347. uclouvain.be

93. Rios, R., Reyes, J., Carvajal, L. P., Rincon, S., Panesso, D., Echeverri, A. M.,... & Diaz, L. (2020). Genomic epidemiology of vancomycin-resistant Enterococcus faecium (VR Efm) in Latin America: Revisiting the global VRE population structure. Scientific reports, 10(1), 5636. nature.com

94. Zhou, X., Willems, R. J., Friedrich, A. W., Rossen, J. W., & Bathoorn, E. (2020). Enterococcus faecium: from microbiological insights to practical recommendations for infection control and diagnostics. Antimicrobial Resistance & Infection Control, 9, 1-13. springer.com

95. Olearo, F., Both, A., Campos, C. B., Hilgarth, H., Klupp, E. M., Hansen, J. L.,... & Rohde, H. (2021). Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. International Journal of Medical Microbiology, 311(2), 151477. sciencedirect.com

96. Werner, G., Neumann, B., Weber, R. E., Kresken, M., Wendt, C., Bender, J. K.,... & Döring, S. (2020). Thirty years of VRE in Germany–"expect the unexpected": The view from the National Reference Centre for Staphylococci and Enterococci. Drug Resistance Updates, 53, 100732. sciencedirect.com

97. O'Toole, R. F., Leong, K. W., Cumming, V., & Van Hal, S. J. (2023). Vancomycin-resistant Enterococcus faecium and the emergence of new sequence types associated with hospital infection. Research in Microbiology, 174(4), 104046. sciencedirect.com

98. Gao, Y., Chen, M., Cai, M., Liu, K., Wang, Y., Zhou, C.,... & Wu, Y. (2022). An analysis of risk factors for carbapenem-resistant Enterobacteriaceae infection. Journal of Global Antimicrobial Resistance, 30, 191-198. sciencedirect.com

99. Jean, S. S., Harnod, D., & Hsueh, P. R. (2022). Global threat of carbapenem-resistant gram-negative bacteria. Frontiers in cellular and

infection microbiology, 12, 823684. frontiersin.org

100. Zhou, R., Fang, X., Zhang, J., Zheng, X., Shangguan, S., Chen, S.,... & Wang, Y. (2021). Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ open, 11(12), e054971. bmj.com

101. Chen, H. Y., Jean, S. S., Lee, Y. L., Lu, M. C., Ko, W. C., Liu, P. Y., & Hsueh, P. R. (2021). Carbapenem-resistant Enterobacterales in long-term care facilities: a global and narrative review. Frontiers in cellular and infection microbiology, 11, 601968. frontiersin.org

102. Predic, M., Delano, J. P., Tremblay, E., Iovine, N., Brown, S., & Prins, C. (2020). Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae. American Journal of Infection Control, 48(9), 1028-1031. [HTML]

103. Guo, B., Guo, Z., Zhang, H., Shi, C., Qin, B., Wang, S.,... & Shao, H. (2022). Prevalence and risk factors of carbapenem-resistant Enterobacterales positivity by active screening in intensive care units in the Henan Province of China: A multi-center cross-sectional study. Frontiers in Microbiology, 13, 894341. frontiersin.org

104. Anju, V. T., Siddhardha, B., & Dyavaiah, M. (2020). Enterobacter infections and antimicrobial drug resistance. Model organisms for microbial pathogenesis, biofilm formation and antimicrobial drug discovery, 175-194. researchgate.net

105. Dougnon, V., Assogba, P., Anago, E., Déguénon, E., Dapuliga, C., Agbankpè, J.,... & Bankolé, H. (2020). Enterobacteria responsible for urinary infections: a review about pathogenicity, virulence factors and epidemiology. Journal of Applied Biology & Biotechnology Vol, 8(01), 117-124. researchgate.net

106. Moxley, R. A. (2022). Family Enterobacteriaceae. Veterinary Microbiology. [HTML]

107. Idrees, H., Khan, S. T., Aftab, M., & Imtiaz, A. (2021). Nosocomial Infections-A Review. LGU J. LIFE SCIENCES. academia.edu

108. Girlich, D., Ouzani, S., Emeraud, C., Gauthier, L., Bonnin, R. A., Le Sache, N.,... & Dortet, L. (2021). Uncovering the novel Enterobacter cloacae complex species responsible for septic shock deaths in newborns: a cohort study. The Lancet Microbe, 2(10), e536-e544. thelancet.com

109. Salimiyan Rizi, K., Ghazvini, K., & Farsiani, H. (2020). Clinical and

pathogenesis overview of Enterobacter infections. Reviews in Clinical Medicine, 6(4), 146-154. archive.org

110. Mullié, C., Lemonnier, D., Adjidé, C. C., Maizel, J., Mismacque, G., Cappe, A.,... & Zerbib, Y. (2022). Nosocomial outbreak of monoclonal VIM carbapenemase-producing Enterobacter cloacae complex in an intensive care unit during the COVID-19 pandemic: an integrated approach. Journal of Hospital Infection, 120, 48-56. sciencedirect.com

111. Gekenidis, M. T., Kläui, A., Smalla, K., & Drissner, D. (2020). Transferable Extended-Spectrum β-Lactamase (ESBL) Plasmids in Enterobacteriaceae from Irrigation Water. Microorganisms. mdpi.com

112. Jung, J., Choi, H. S., Lee, J. Y., Ryu, S. H., Kim, S. K., Hong, M. J.,... & Kim, S. H. (2020). Outbreak of carbapenemase-producing Enterobacteriaceae associated with a contaminated water dispenser and sink drains in the cardiology units of a Korean hospital. Journal of Hospital Infection, 104(4), 476-483. [HTML]

113. Praja, R. N., Yudhana, A., Haditanojo, W., & Oktaviana, V. (2021). Antimicrobial properties in cloacal fluid of olive ridley sea turtle (Lepidochelys olivacea). Biodiversitas: Journal of Biological Diversity, 22(9). uns.ac.id

114. Marchiani, S., Baccani, I., Tamburrino, L., Mattiuz, G., Nicolò, S., Bonaiuto, C.,... & Baldi, E. (2021). Effects of common Gram-negative pathogens causing male genitourinary-tract infections on human sperm functions. Scientific reports, 11(1), 19177. nature.com

115. Hussein, E. F. (2022). Pseudomonas aeruginosa Represents a Main Cause of Hospital-Acquired Infections (HAI) and Multidrug Resistance (MDR). In Pseudomonas aeruginosa-New Perspectives and Applications. IntechOpen. intechopen.com

116. Church, N. A. & McKillip, J. L. (2021). Antibiotic resistance crisis: challenges and imperatives. Biologia. [HTML]

117. Bakhtiyari, N., Farajnia, S., Ghasemali, S., Farajnia, S., Pormohammad, A., & Saeidvafa, S. (2024). Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 24(6), 49-62. [HTML]

118. Chinemerem Nwobodo, D., Ugwu, M. C., Oliseloke Anie, C., Al-Ouqaili, M. T., Chinedu Ikem, J., Victor Chigozie, U., & Saki, M. (2022). Antibiotic resistance: The challenges and some emerging strategies for

tackling a global menace. Journal of clinical laboratory analysis, 36(9), e24655. wiley.com

119. Di Franco, S., Alfieri, A., Pace, M. C., Sansone, P., Pota, V., Fittipaldi, C.,... & Passavanti, M. B. (2021). Blood stream infections from MDR bacteria. Life, 11(6), 575. mdpi.com

120. Owusu, E. G. A. (2020). Light-Activated Antimicrobial Surfaces Containing Quantum Dots for the Prevention of Hospital-Acquired Infections. ucl. ac. uk

121. Almatroudi, A. (2022). Patients' safety and hospital acquired infections: the size of the problem of biofilms on the health care surfaces. mq.edu. au

122. Stefanini, I., Boni, M., Silvaplana, P., Lovera, P., Pelassa, S., De Renzi, G., & Mognetti, B. (2020). Antimicrobial resistance, an update from the Ward: Increased incidence of new potential pathogens and site of infection-specific antibacterial resistances. Antibiotics, 9(9), 631. mdpi.com

123. Szabó, S., Feier, B., Capatina, D., Tertis, M., Cristea, C., & Popa, A. (2022). An overview of healthcare associated infections and their detection methods caused by pathogen bacteria in Romania and Europe. Journal of clinical medicine, 11(11), 3204. mdpi.com

124. Valzano, F., Coda, A. R. D., Liso, A., & Arena, F. (2024). Multidrug-Resistant Bacteria Contaminating Plumbing Components and Sanitary Installations of Hospital Restrooms. Microorganisms. mdpi.com

125. Pauter, K., Szultka-Młyńska, M., & Buszewski, B. (2020). Determination and identification of antibiotic drugs and bacterial strains in biological samples. Molecules. mdpi.com

126. Hassoun-Kheir, N., Stabholz, Y., Kreft, J. U., De La Cruz, R., Romalde, J. L., Nesme, J.,... & Paul, M. (2020). Comparison of antibiotic-resistant bacteria and antibiotic resistance genes abundance in hospital and community wastewater: A systematic review. Science of the Total Environment, 743, 140804. [HTML]

127. Mancuso, G., Midiri, A., Gerace, E., & Biondo, C. (2021). Bacterial antibiotic resistance: the most critical pathogens. Pathogens. mdpi.com

128. Urban-Chmiel, R., Marek, A., Stępień-Pyśniak, D., Wieczorek, K., Dec, M., Nowaczek, A., & Osek, J. (2022). Antibiotic resistance in bacteria—A review. Antibiotics, 11(8), 1079. mdpi.com

129. Assefa, M. & Amare, A. (2022). Biofilm-associated multi-drug resistance in hospital-acquired infections: A review. Infection and drug resistance. tandfonline.com

130. Avershina, E., Shapovalova, V., & Shipulin, G. (2021). Fighting antibiotic resistance in hospital-acquired infections: current state and emerging technologies in disease prevention, diagnostics and therapy. Frontiers in microbiology. frontiersin.org

131. Morris, S. & Cerceo, E. (2020). Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics. mdpi.com

132. Hammoudi Halat, D. & Ayoub Moubareck, C. (2020). The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria. Antibiotics. mdpi.com